

GLOBAL JOURNAL

OF MEDICAL RESEARCH: C

Microbiology & Pathology

Merkel Cell Carcinoma

Multi-Resistant Strain

Highlights

Staphylococcus Epidermidis

Antibiotics in Staphylococcus

Discovering Thoughts, Inventing Future

VOLUME 14

ISSUE 2

VERSION 1.0



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY

VOLUME 14 ISSUE 2 (VER. 1.0)

OPEN ASSOCIATION OF RESEARCH SOCIETY

© Global Journal of Medical
Research . 2014.

All rights reserved.

This is a special issue published in version 1.0
of "Global Journal of Medical Research." By
Global Journals Inc.

All articles are open access articles distributed
under "Global Journal of Medical Research"

Reading License, which permits restricted use.
Entire contents are copyright by of "Global
Journal of Medical Research" unless
otherwise noted on specific articles.

No part of this publication may be reproduced
or transmitted in any form or by any means,
electronic or mechanical, including
photocopy, recording, or any information
storage and retrieval system, without written
permission.

The opinions and statements made in this
book are those of the authors concerned.
Ultraculture has not verified and neither
confirms nor denies any of the foregoing and
no warranty or fitness is implied.

Engage with the contents herein at your own
risk.

The use of this journal, and the terms and
conditions for our providing information, is
governed by our Disclaimer, Terms and
Conditions and Privacy Policy given on our
website [http://globaljournals.us/terms-and-condition/
menu-id-1463/](http://globaljournals.us/terms-and-condition/menu-id-1463/)

By referring / using / reading / any type of
association / referencing this journal, this
signifies and you acknowledge that you have
read them and that you accept and will be
bound by the terms thereof.

All information, journals, this journal,
activities undertaken, materials, services and
our website, terms and conditions, privacy
policy, and this journal is subject to change
anytime without any prior notice.

Incorporation No.: 0423089
License No.: 42125/022010/1186
Registration No.: 430374
Import-Export Code: 1109007027
Employer Identification Number (EIN):
USA Tax ID: 98-0673427

Global Journals Inc.

(A Delaware USA Incorporation with "Good Standing"; **Reg. Number: 0423089**)
*Sponsors: Open Association of Research Society
Open Scientific Standards*

Publisher's Headquarters office

Global Journals Headquarters
301st Edgewater Place Suite, 100 Edgewater Dr.-Pl,
Wakefield MASSACHUSETTS, Pin: 01880,
United States of America
USA Toll Free: +001-888-839-7392
USA Toll Free Fax: +001-888-839-7392

Offset Typesetting

Global Journals Incorporated
2nd, Lansdowne, Lansdowne Rd., Croydon-Surrey,
Pin: CR9 2ER, United Kingdom

Packaging & Continental Dispatching

Global Journals
E-3130 Sudama Nagar, Near Gopur Square,
Indore, M.P., Pin:452009, India

Find a correspondence nodal officer near you

To find nodal officer of your country, please
email us at local@globaljournals.org

eContacts

Press Inquiries: press@globaljournals.org
Investor Inquiries: investors@globaljournals.org
Technical Support: technology@globaljournals.org
Media & Releases: media@globaljournals.org

Pricing (Including by Air Parcel Charges):

For Authors:

22 USD (B/W) & 50 USD (Color)
Yearly Subscription (Personal & Institutional):
200 USD (B/W) & 250 USD (Color)

INTEGRATED EDITORIAL BOARD
(COMPUTER SCIENCE, ENGINEERING, MEDICAL, MANAGEMENT, NATURAL
SCIENCE, SOCIAL SCIENCE)

John A. Hamilton, "Drew" Jr.,
Ph.D., Professor, Management
Computer Science and Software
Engineering
Director, Information Assurance
Laboratory
Auburn University

Dr. Henry Hexmoor
IEEE senior member since 2004
Ph.D. Computer Science, University at
Buffalo
Department of Computer Science
Southern Illinois University at Carbondale

Dr. Osman Balci, Professor
Department of Computer Science
Virginia Tech, Virginia University
Ph.D. and M.S. Syracuse University,
Syracuse, New York
M.S. and B.S. Bogazici University,
Istanbul, Turkey

Yogita Bajpai
M.Sc. (Computer Science), FICCT
U.S.A. Email:
yogita@computerresearch.org

Dr. T. David A. Forbes
Associate Professor and Range
Nutritionist
Ph.D. Edinburgh University - Animal
Nutrition
M.S. Aberdeen University - Animal
Nutrition
B.A. University of Dublin- Zoology

Dr. Wenying Feng
Professor, Department of Computing &
Information Systems
Department of Mathematics
Trent University, Peterborough,
ON Canada K9J 7B8

Dr. Thomas Wischgoll
Computer Science and Engineering,
Wright State University, Dayton, Ohio
B.S., M.S., Ph.D.
(University of Kaiserslautern)

Dr. Abdurrahman Arslanyilmaz
Computer Science & Information Systems
Department
Youngstown State University
Ph.D., Texas A&M University
University of Missouri, Columbia
Gazi University, Turkey

Dr. Xiaohong He
Professor of International Business
University of Quinnipiac
BS, Jilin Institute of Technology; MA, MS,
PhD., (University of Texas-Dallas)

Burcin Becerik-Gerber
University of Southern California
Ph.D. in Civil Engineering
DDes from Harvard University
M.S. from University of California, Berkeley
& Istanbul University

Dr. Bart Lambrecht

Director of Research in Accounting and Finance
Professor of Finance
Lancaster University Management School
BA (Antwerp); MPhil, MA, PhD
(Cambridge)

Dr. Carlos García Pont

Associate Professor of Marketing
IESE Business School, University of Navarra
Doctor of Philosophy (Management),
Massachusetts Institute of Technology (MIT)
Master in Business Administration, IESE,
University of Navarra
Degree in Industrial Engineering,
Universitat Politècnica de Catalunya

Dr. Fotini Labropulu

Mathematics - Luther College
University of Regina
Ph.D., M.Sc. in Mathematics
B.A. (Honors) in Mathematics
University of Windsor

Dr. Lynn Lim

Reader in Business and Marketing
Roehampton University, London
BCom, PGDip, MBA (Distinction), PhD,
FHEA

Dr. Mihaly Mezei

ASSOCIATE PROFESSOR
Department of Structural and Chemical
Biology, Mount Sinai School of Medical
Center
Ph.D., Eötvös Loránd University
Postdoctoral Training,
New York University

Dr. Söhnke M. Bartram

Department of Accounting and Finance
Lancaster University Management School
Ph.D. (WHU Koblenz)
MBA/BBA (University of Saarbrücken)

Dr. Miguel Angel Ariño

Professor of Decision Sciences
IESE Business School
Barcelona, Spain (Universidad de Navarra)
CEIBS (China Europe International Business School).
Beijing, Shanghai and Shenzhen
Ph.D. in Mathematics
University of Barcelona
BA in Mathematics (Licenciatura)
University of Barcelona

Philip G. Moscoso

Technology and Operations Management
IESE Business School, University of Navarra
Ph.D in Industrial Engineering and
Management, ETH Zurich
M.Sc. in Chemical Engineering, ETH Zurich

Dr. Sanjay Dixit, M.D.

Director, EP Laboratories, Philadelphia VA
Medical Center
Cardiovascular Medicine - Cardiac
Arrhythmia
Univ of Penn School of Medicine

Dr. Han-Xiang Deng

MD., Ph.D
Associate Professor and Research
Department Division of Neuromuscular
Medicine
Department of Neurology and Clinical
Neuroscience
Northwestern University
Feinberg School of Medicine

Dr. Pina C. Sanelli

Associate Professor of Public Health
Weill Cornell Medical College
Associate Attending Radiologist
NewYork-Presbyterian Hospital
MRI, MRA, CT, and CTA
Neuroradiology and Diagnostic
Radiology
M.D., State University of New York at
Buffalo, School of Medicine and
Biomedical Sciences

Dr. Roberto Sanchez

Associate Professor
Department of Structural and Chemical
Biology
Mount Sinai School of Medicine
Ph.D., The Rockefeller University

Dr. Wen-Yih Sun

Professor of Earth and Atmospheric
SciencesPurdue University Director
National Center for Typhoon and
Flooding Research, Taiwan
University Chair Professor
Department of Atmospheric Sciences,
National Central University, Chung-Li,
TaiwanUniversity Chair Professor
Institute of Environmental Engineering,
National Chiao Tung University, Hsin-
chu, Taiwan.Ph.D., MS The University of
Chicago, Geophysical Sciences
BS National Taiwan University,
Atmospheric Sciences
Associate Professor of Radiology

Dr. Michael R. Rudnick

M.D., FACP
Associate Professor of Medicine
Chief, Renal Electrolyte and
Hypertension Division (PMC)
Penn Medicine, University of
Pennsylvania
Presbyterian Medical Center,
Philadelphia
Nephrology and Internal Medicine
Certified by the American Board of
Internal Medicine

Dr. Bassey Benjamin Esu

B.Sc. Marketing; MBA Marketing; Ph.D
Marketing
Lecturer, Department of Marketing,
University of Calabar
Tourism Consultant, Cross River State
Tourism Development Department
Co-ordinator , Sustainable Tourism
Initiative, Calabar, Nigeria

Dr. Aziz M. Barbar, Ph.D.

IEEE Senior Member
Chairperson, Department of Computer
Science
AUST - American University of Science &
Technology
Alfred Naccash Avenue – Ashrafieh

PRESIDENT EDITOR (HON.)

Dr. George Perry, (Neuroscientist)

Dean and Professor, College of Sciences

Denham Harman Research Award (American Aging Association)

ISI Highly Cited Researcher, Iberoamerican Molecular Biology Organization

AAAS Fellow, Correspondent Member of Spanish Royal Academy of Sciences

University of Texas at San Antonio

Postdoctoral Fellow (Department of Cell Biology)

Baylor College of Medicine

Houston, Texas, United States

CHIEF AUTHOR (HON.)

Dr. R.K. Dixit

M.Sc., Ph.D., FICCT

Chief Author, India

Email: authorind@computerresearch.org

DEAN & EDITOR-IN-CHIEF (HON.)

Vivek Dubey(HON.)

MS (Industrial Engineering),

MS (Mechanical Engineering)

University of Wisconsin, FICCT

Editor-in-Chief, USA

editorusa@computerresearch.org

Sangita Dixit

M.Sc., FICCT

Dean & Chancellor (Asia Pacific)

deanind@computerresearch.org

Suyash Dixit

(B.E., Computer Science Engineering), FICCTT

President, Web Administration and

Development , CEO at IOSRD

COO at GAOR & OSS

Er. Suyog Dixit

(M. Tech), BE (HONS. in CSE), FICCT

SAP Certified Consultant

CEO at IOSRD, GAOR & OSS

Technical Dean, Global Journals Inc. (US)

Website: www.suyogdixit.com

Email: suyog@suyogdixit.com

Pritesh Rajvaidya

(MS) Computer Science Department

California State University

BE (Computer Science), FICCT

Technical Dean, USA

Email: pritesh@computerresearch.org

Luis Galárraga

J!Research Project Leader

Saarbrücken, Germany

CONTENTS OF THE VOLUME

- i. Copyright Notice
- ii. Editorial Board Members
- iii. Chief Author and Dean
- iv. Table of Contents
- v. From the Chief Editor's Desk
- vi. Research and Review Papers
 1. Evaluation of Sensitivity of Commonly used Antibiotics in *Staphylococcus Epidermidis* Clinical Isolates from Assir Region, Saudi Arabia . **1-7**
 2. Merkel Cell Carcinoma : An Indian Experience. **9-13**
 3. Opportunistic Infections Vs Immune Suppression among HIV Seropositive Individuals in East Godavari District, Andhra Pradesh. **15-19**
 4. Fatal Pulmonary Infection by a Multi-Resistant Strain of C.Laurentii in a Patient with Active Pulmonary Tuberculosis. **21-24**
 5. Hyper-Immunoglobulin E Syndrome in a Neonate: A Case Report. **25-27**
 6. *Staphylococcus aureus* and its Antimicrobial Susceptibility Pattern in Patients, Nasalcarage of Health Personnel, and Objects at Dessie Referral Hospital, Northern Ethiopia. **29-36**
- vii. Auxiliary Memberships
- viii. Process of Submission of Research Paper
- ix. Preferred Author Guidelines
- x. Index



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY
Volume 14 Issue 2 Version 1.0 Year 2014
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Evaluation of Sensitivity of Commonly used Antibiotics in Staphylococcus Epidermidis Clinical Isolates From Assir Region, Saudi Arabia

By Nazar Mohamed Abdalla, Waleed Omer Haimour, Amani Ali Osman,
Faten Mohamed ElAbd, Hassan Abdulaziz Musa
& Mohamed Nazar Mohamed
Medicine/ Gezira University, Saudi Arabia

Abstract- Background: Multidrug resistance is an emerging health problem that ultimately will lead to vanishing of effective medicine against infections including Staphylococcus epidermidis infections.

Aim: This a prospective hospital base study of 58 Staphylococcus epidermidis clinical isolates in Assir region aim at evaluating the sensitivity profile of commonly used antibiotic during the period of March 2011- Sep. 2011.

Materials and Methods: Bacteriology procedures ; staining, culture, catalase, coagulase and antibiotics sensitivity test using diffusion disc test, minimum inhibitory concentration (MIC) and molecular (PCR) for confirmation of Staphylococcal species and detection of the Mec A gene.

Keywords: *staphylococcus epidermidis, coagulase negative staphylococci (CoNS), antimicrobial resistance (AMR), nosocomial infections, diabetes.*

GJMR-C Classification : NLMC Code: QV 268, QV 269



EVALUATION OF SENSITIVITY OF COMMONLY USED ANTIBIOTICS IN STAPHYLOCOCCUS EPIDERMIDIS CLINICAL ISOLATES FROM ASSIR REGION SAUDI ARABIA

Strictly as per the compliance and regulations of:



© 2014. Nazar Mohamed Abdalla, Waleed Omer Haimour, Amani Ali Osman, Faten Mohamed ElAbd, Hassan Abdulaziz Musa & Mohamed Nazar Mohamed. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Evaluation of Sensitivity of Commonly used Antibiotics in *Staphylococcus Epidermidis* Clinical Isolates From Assir Region, Saudi Arabia

Nazar Mohamed Abdalla ^α, Waleed Omer Haimour ^σ, Amani Ali Osman ^ρ, Faten Mohamed ElAbd ^ω, Hassan Abdulaziz Musa [¥] & Mohamed Nazar Mohamed [§]

Abstract- Background: Multidrug resistance is an emerging health problem that ultimately will lead to vanishing of effective medicine against infections including *Staphylococcus epidermidis* infections.

Aim: This a prospective hospital base study of 58 *Staphylococcus epidermidis* clinical isolates in Assir region aim at evaluating the sensitivity profile of commonly used antibiotic during the period of March 2011- Sep. 2011.

Materials and Methods: Bacteriology procedures ; staining, culture, catalase, coagulase and antibiotics sensitivity test using diffusion disc test, minimum inhibitory concentration (MIC) and molecular (PCR) for confirmation of *Staphylococcal* species and detection of the *Mec A* gene. Clinical and laboratory data were recorded in special formats and analyzed by statistical computer program (SPSS).

Result: 58 *Staphylococcus epidermidis* clinical isolates including 14 diabetics. Age groups include 29 (0-15yrs), 14 (16-50yrs) and 15 (50yrs & above). The total resistance cases to Oxacillin/ Mithicillin was found to be 56 cases (96.4%); all non diabetics were resistance. Resistance and sensitivity to Ciprofloxacin among diabetic and non diabetic were 75.9% and 24.1% respectively. Total resistance to Fusidin were 81%, while total resistant to Erythromycin in all ages groups were 86.2%. In age group (0-15) years 93.1% were resistant to the drug which comprises, 54% of the total resistant cases (n=50) and 46.6% from all *Staphylococcus epidermidis* cases (n=58).

Conclusion: *Staphylococcus epidermidis* is a pathogen associated with community acquired and nosocomial infections. The nosocomial infections are predominant in neonatal intensive care units (NICU). Resistance of Erythromycin in *S. epidermidis* cases among children is highly observed as this drug is commonly used by this age group. Diabetes has equivocal effect on drugs sensitivity. The frequency of *staphylococcus* multi-drugs resistance is rising.

Author α: Consultant Medical Microbiologist, College of Medicine, King Khalid University, Abha, Saudi Arabia. e-mail: uofgnazar@gmail.com

Author σ ω: Microbiology Specialist, Assir Central Hospital Lab, Abha, Saudi Arabia.

Author ρ: Consultant Reproductive Health, Family & Community Medicine Department, College of Medicine, King Khalid University, Abha, Saudi Arabia.

Author ¥: Consultant Microbiologist, The Vice Chancellor's Assistant for Academic Affairs, The National Ribat University, Khartoum, Sudan.

Author §: Medical Officer, Khartoum Hospital, Ministry of Health, Sudan.

Keywords: *staphylococcus epidermidis*, coagulase-negative staphylococci (CoNS), antimicrobial resistance (AMR), nosocomial infections, diabetes.

I. INTRODUCTION

Friedrich Julius Rosenbach distinguished *S. epidermidis* from *S. aureus* in 1884, initially naming *S. epidermidis* as *S. albus*. He chose *aureus* and *albus* since the bacteria formed yellow and white colonies, respectively. *S. epidermidis* causing nosocomial and community acquired infections [1]

S. epidermidis is a very hardy microorganism, consisting of nonmotile, Gram-positive cocci, arranged in grape-like clusters. It forms white, raised colonies approximately 1–2 millimeter in diameter after overnight incubation, and is nonhemolytic on blood agar. It is a catalase-positive, coagulase-negative, facultative anaerobe that can grow by aerobic respiration or by fermentation. Some strains may not ferment [2].

Biochemical tests indicate this microorganism also carries out a weakly positive reaction to the nitrate reductase test. It is positive for urease production, is oxidase negative, and can use glucose, sucrose, and lactose to form acid products. In the presence of lactose, it will also produce gas. *S. epidermidis* does not possess the gelatinase enzyme, so it cannot hydrolyze gelatin. It is sensitive to novobiocin, providing an important test to distinguish it from *Staphylococcus saprophyticus*, which is coagulase-negative, as well, but novobiocin-resistant. Similar to those of *Staphylococcus aureus*, the cell walls of *S. epidermidis* have a transferrin binding protein that helps the organism obtain iron from transferrin. The tetramers of a surface exposed protein, glyceraldehyde-3-phosphate dehydrogenase, are believed to bind to transferrin and remove its iron. Subsequent steps include iron being transferred to surface lipoproteins, then to transport proteins which carry the iron into the cell [3] ³. The normal practice of detecting *S. epidermidis* is by using the Baird-Parker agar with egg yolk supplement. Colonies appear small and black. They can be confirmed using the coagulase test. Increasingly, techniques such as real-time PCR and

quantitative PCR are being employed for the rapid detection and identification of *Staphylococcus* strains [4]⁴. Normally, sensitivity to desferrioxamine can also be used to distinguish it from most other staphylococci, except in the case of *Staphylococcus hominis*, which is also sensitive. In this case, the production of acid from trehalose by *S. hominis* can be used to tell the two species apart.

Resistance to antimicrobial agents (AMR) has resulted in morbidity and mortality from treatment failures and increased health care costs. Although defining the precise public health risk and estimating the increase in costs is not a simple undertaking, there is little doubt that emergent antibiotic resistance is a serious global problem. Appropriate antimicrobial drug use has unquestionable benefit, but physicians and the public frequently use these agents inappropriately.

Aseer Central Hospital is almost 600 bedded and it is accredited from The Central Board of Arab Health. It's laboratory is a regional referral hub. The other hand, the hospital is affiliated to the medical college of King Khalid University. This study aimed at evaluating the commonly used antibiotics resistant and the factors affecting the drugs sensitivity of *Staphylococcus epidermidis* isolates from nasal swabs of patients presented at Aseer Central Hospital General Lab.

II. MATERIAL AND METHODS

The patients in this study were informed about the study content and procedures with preservation of human rights in concordance with the research ethics of the Deanship of Scientific Research and Research Center For Medical College, King Khalid University, Kingdom of Saudi Arabia.

A total of 58 clinical isolates including; respiratory infection, central nervous system infections, urogenital infection, musculoskeletal (Joints) infections and skin infection were included. Blood, urine and swabs (nasal, skin and conjunctivae) specimens have been tested by bacteriology, chemical and PCR Assay. Bacteriology procedures ; staining, culture, catalase, coagulase and antibiotics sensitivity test using diffusion disc test, minimum inhibitory concentration (MIC) [5] and molecular (PCR) for confirmation of *Staphylococcal* species [6] and detection of the Mec A gene [7]. General primers for detection of positive *Staphylococcal* isolates not carrying the Mc Agene were used. The codes and sequences of the primers (50 pmol of primer per reaction) were as follows: ERIC-1R, 59-ATG TAA GCT CCT GGG GAT TCA C-39; ERIC-2, 59-AAG TAA GTG ACT GGG GTG AGC G-39; (*Staphylococcus epidermidis* ATCC 12228 chromosome, complete genome NCBI Reference Sequence: NC_004461.1). The PCR mixture was overlaid with 5 ul of mineral oil to prevent evaporation. Amplification of DNA fragments was performed in a Biomed thermo-cycler (model 60; Biomed, Theres, Germany) with predenaturation at 94C°

for 4 min, followed by 40 cycles of 1 min at 94C°, 1 min at 55C°, and 2 min at 74 C°. Amplicons were analyzed by agarose gel electrophoresis containing 1% agarose (Hispanagar; Sph. Leiden, The Netherlands) in 0.53 Tris-borate-EDTA (TBE) in the presence of ethidium bromide (0.03 mg/ml) at a constant current of 100 mA for 1 h.

a) Statistical Study

Clinical and Laboratory data were recorded in special formats and entered in stat computer program (SPSS). Descriptive and analytical statistical analysis were performed and final results were plotted in tables.

III. RESULTS

58 *Staphylococcus epidermidis* and negative Mec A gene clinical isolates including 14 diabetics. Age groups include 29 (0-15yrs), 14 (16-50yrs) and 15 (50yrs& above). 29 patients (50%) have presented with skin sepsis this due to the fact that *S. epidermidis* is a known normal flora of the skin. Distribution of patients according to their sex and diagnosis . Table 1.

Distribution of patients according to their presence in hospital revealed that; 35 patients were in intensive care units and 24 patients were in PICU and NICU (Pediatric and Neonates). Table 2.

The total resistance cases to Oxacillin/ Mithicillin was found to be 56 cases (96.4%); 12 diabetic patients (21.4%) and 44 non diabetic (78.6%). So all non diabetics were resistance. Table 3.

Resistance and sensitivity to Ciprofloxacin in all 58 *Staphylococcus epidermidis* diabetic and non diabetic patients under study were 75.9% and 24.1% respectively. Table 4.

Total resistance to Fusidin were 47 cases (81%) and total sensitivity to Fusidin were 11 cases (19%). Table 5

Total resistant and sensitivity to Erythromycin in all ages groups were 86.2% and 13.8% respectively. In age group (0-15) years 93.1% were resistant to the drug which comprises, 54% of the total resistant cases (n=50) and 46.6% from all *Staphylococcus epidermidis* cases (n=58). Table 6.

Table 1 : Distribution of patients according to their sex and diagnosis

Diagnosis	Sex		Total
	Male	Female	
Acute Abdomen	0	1	1
Sepsis	18	11	29
URI	2	0	2
Post Surgery	0	1	1
CVA	4	3	7
ESRD	1	0	1
RDS	1	0	1
PUO(Pyrexia)	1	0	1
ELEC Burn	1	0	1
Trauma	1	1	2
RTA	7	0	7
Head Inj.	1	1	2
DM	2	1	3
Total	39	19	58

Table 2 : Distribution of patients according to age group in different departments

Department	Age			Total
	(0- 15)years	(16 – 50) years	51 years and more	
OPD	2	4	2	8
MMW	0	0	1	1
MFSW	1	0	0	1
MSW	1	0	2	3
FMW	0	1	2	3
PMW	1	0	0	1
ER	1	1	0	2
PICU	15	1	0	16
MOW	0	0	1	1
ICU	0	2	2	4
IMCU	0	2	4	6
CCU	0	0	1	1
NICU	8	0	0	8
BU	0	1	0	1
MNW	0	1	0	1
MUW	0	1	0	1
Total	29	14	15	58

Table 3 : Crosstabs showed Oxacillin/ Mithicillin sensitivity and resistance in *Staphylococcus epidermidis* positive cases among diabetics and non diabetics

Antibiotic sensitivity profile			Diabetes mellitus		Total	
			Yes	No	Yes	
Oxacillin/ Mithicillin	R	Count	12	44	56	
		% within Oxacillin/ Mithicillin	21,4%	78,6%	100,0%	
		% within Diabetes mellitus	85,7%	100,0%	96,6%	
		% of Total	20,7%	75,9%	96,6%	
	S	Count	2	0	2	
		% within Oxacillin/ Mithicillin	100,0%	,0%	100,0%	
		% within Diabetes mellitus	14,3%	,0%	3,4%	
		% of Total	3,4%	,0%	3,4%	
Total			Count	14	44	58
			% within Oxacillin/ Mithicillin	24,1%	75,9%	100,0%
			% within Diabetes mellitus	100,0%	100,0%	100,0%
			% of Total	24,1%	75,9%	100,0%

Table 4 : Crosstabs showed Ciprofloxacin sensitivity and resistance in *Staphylococcus epidermidis* positive cases among diabetics and non diabetics

Antibiotic sensitivity profile			Diabetes mellitus		Total	
			Yes	No	Yes	
Ciprofloxacin	R	Count	10	34	44	
		% within Ciprofloxacin	19,5%	80,5%	100,0%	
		% within Diabetes mellitus	57,1%	75,0%	70,7%	
		% of Total	13,8%	56,9%	70,7%	
	S	Count	4	10	14	
		% within Ciprofloxacin	28,6%	71,4%	100,0%	
		% within Diabetes mellitus	28,6%	22,7%	24,1%	
		% of Total	6,9%	17,2%	24,1%	
	Total			14	44	58
				24.1%	75.9%	100%

Table 5 : Crosstabs showed Fusidin sensitivity and resistance in *Staphylococcus epidermidis* positive cases

Antibiotic sensitivity profile			Diabetes mellitus		Total	
			yes	no		
Fusidin	R	Count	11	36	47	
		% within Fusidin	18,5%	81,5%	100,0%	
		% within Diabetes mellitus	78,5%	81,8%	81%	
		% of Total	18,9%	62,1%	81%	
	S	Count	3	8	11	
		% within Fusidin	27,3%	72,7%	100,0%	
		% within Diabetes mellitus	21,4%	18,2%	19,0%	
		% of Total	5,2%	13,8%	19,0%	
	Total			14	44	58
				24.1%	75.9%	100%

Table 6 : Crosstabs showed Erythromycin sensitivity and resistance in *Staphylococcus epidermidis* positive cases among different age groups

Antibiotic sensitivity profile			age group			Total
			0-15	16-50	51+	
Erythromycin	R	Count	27	11	12	50
		% within Erythromycin	54 %	22 %	24 %	100,0%
		% within age group	93,1%	78,6%	80 %	84,5%
		% of Total	46,6%	19,0%	19,0%	86,2%
	S	Count	2	3	3	8
		% within Erythromycin	25,0%	37,5%	37,5%	100,0%
		% within age group	6,9%	21,4%	20,0%	13,8%
		% of Total	3,4%	5,2%	5,2%	13,8%
Total	Count	29	14	15	58	
	% within Erythromycin	50,0%	24,1%	25,9%	100,0%	
	% within age group	100,0%	100,0%	100,0%	100,0%	
	% of Total	50,0%	24,1%	25,9%	100,0%	

IV. DISCUSSION

Staphylococcus epidermidis is one of 33 known species belonging to the genus *Staphylococcus*. The taxonomy of this bacteria is; Kingdom: Bacteria. Phylum: Firmicutes. Class: Cocci. Order: Bacillales. Family: Staphylococcaceae. Genus: *Staphylococcus*. Species: *S. epidermidis*. It is part of human skin flora (commensal), and consequently part of human flora. It can also be found in the mucous membranes and in animals. Due to contamination, it is probably the most common species found in laboratory tests [8]⁷. Although *S. epidermidis* is not usually pathogenic, patients with compromised immune systems are often at risk for developing an infection. These infections can be both nosocomial or community acquired, *S. epidermidis* is also a major concern for people with catheters or other surgical implants because it is known to cause biofilms that grow on these devices [9]⁸. *S. epidermidis* causes biofilms to grow on plastic devices placed within the body [10]⁹. This occurs most commonly on intravenous catheters and on medical prostheses. Infection can also occur in dialysis patients or anyone with an implanted plastic device that may have been contaminated. Another disease it causes endocarditis [11]. In some other cases, sepsis can occur in hospital patients. Resistant organisms are most commonly found in the intestine, but organisms living freely on the skin can also become resistant due to routine exposure to antibiotics secreted in sweat [12]¹². Detection of the *mecA* gene by polymerase chain reaction (PCR) is the gold standard for identifying methicillin-resistant *Staphylococcus aureus* (MRSA). PCR assays, employing MR1-MR2 primers (primer set 1) and MR3-MR4 primers (primer set 2) to generate 154 and 533 bp fragment, respectively,

are most widely used for amplification of *mecA* gene [13]¹³. Spread of *S. spp.* (including MRSA) generally is through human-to-human contact, although recently some veterinarians have discovered the infection can be spread through pets, with environmental contamination. Cases of *S. spp.* Nosocomial infections have reported to be transported by polyester, the main material used in hospital curtains in hospitals across America [14]¹⁴. An important and previously unrecognized means of community-associated MRSA colonization and transmission is during sexual contact [15]¹⁵. It was discovered that there are two different strains of *S. epidermidis*, one that inhibits biofilm formation by *S. aureus*, *S. epidermidis* strain JK16 (inhibitory type), and one that does not (non-inhibitory type) *S. epidermidis* strain JK11 [16]¹⁶. Staphylococcal resistance to penicillin is mediated by penicillinase (a form of β -lactamase) production: an enzyme that cleaves the β -lactam ring of the penicillin molecule, rendering the antibiotic ineffective. Penicillinase-resistant β -lactam antibiotics, such as methicillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, and flucloxacillin, are able to resist degradation by staphylococcal penicillinase. Resistance to methicillin is mediated via the *mec* operon, part of the staphylococcal cassette chromosome *mec* (SCC*mec*). Resistance is conferred by the *mecA* gene, which codes for an altered penicillin-binding protein (PBP2a or PBP2') that has a lower affinity for binding β -lactams (penicillins, cephalosporins, and carbapenems). This allows for resistance to all β -lactam antibiotics, and obviates their clinical use during MRSA infections. As such, the glycopeptide vancomycin is often deployed against MRSA [17]¹⁷. Aminoglycoside antibiotics, such as kanamycin, gentamicin, streptomycin, etc., were once effective against staphylococcal infections until strains

evolved mechanisms to inhibit the aminoglycosides' action, which occurs via protonated amine and/or hydroxyl interactions with the ribosomal RNA of the bacterial 30S ribosomal subunit [18]¹⁸. There are three main mechanisms of aminoglycoside resistance mechanisms which are currently and widely accepted: aminoglycoside modifying enzymes, ribosomal mutations, and active efflux of the drug out of the bacteria [19]¹⁹. MRSA infections in both the hospital and community setting are commonly treated with non- β -lactam antibiotics, such as clindamycin (a lincosamine) and co-trimoxazole (also commonly known as trimethoprim/ sulfamethoxazole). Resistance to these antibiotics has also led to the use of new, broad-spectrum anti-Gram-positive antibiotics, such as linezolid, because of its availability as an oral drug. So it is nowadays highly recommended to use combined therapy to treat severe cases of *S. aureus* infections such as pneumonia, meningitis and toxic shock syndrome [20].²⁰ All 29 *S. epidermidis* isolates were found to be resistant to oxacillin and were positive for the *mecA* gene. The isolates showed several multidrug-resistance patterns; the resistance rates to gentamicin, erythromycin, clindamycin, and [21] were susceptible to vancomycin, teicoplanin, rifampin, synercid, and ciprofloxacin. Several genotypic and phenotypic patterns were detected among the *S. epidermidis* isolates: antibiogram typing showed seven different patterns, one of which was shared by 65% of the isolates, whereas the most prevalent RAPD genotype was shared by only five *S. epidermidis* isolates [22], and did not correlate with antibiotic resistance phenotype. The diverse clonal origin of tested isolates indicates the presence of multiple *S. epidermidis* strains among neonates in the NICU setting [23]²¹. In another study the nasal carriage of methicillin-resistant coagulase-negative staphylococci (MR-CoNS) is highly prevalent in community subjects [24]²². Few studies on staphylococcal infections and drugs sensitivity were conducted in Saudi Arabia [25] [26] [27].^{24, 25, 26} Resistance is conferred by Penicillinase-resistant β -lactam antibiotics and the *mec A* gene, which codes for an altered penicillin-binding protein (PBP') that has a lower affinity for binding β -lactams (penicillins, cephalosporins, and carbapenems). This allows for resistance to all β -lactam antibiotics, and obviates their clinical use during MRSA infections. *Mec A* gene is known associated factor of drug resistance for Oxacillin/Mithcillin drug as all isolates were *Mec A* gene negative, the resistance could be explained by the thick biofilm caused by this bacteria which guard against drug penetration [28] [29],

V. ACKNOWLEDGEMENT

We confer our gratitude to the laboratory of Assir Central Hospital. Our sincere thanks to the department of microbiology, College of Medicine, King

Khalid University (Saudi Arabia) and Ribat National University (Sudan).

VI. CONCLUSION

Staphylococcus epidermidis is a pathogen associated with community acquired and nosocomial infections. These infections were predominant among children in neonatal intensive care units (NICU) .

Resistance of Erythromycin in *S. epidermidis* cases among children is highly observed as this drug is commonly used by this age group.

Diabetes has equivocal effect on drugs sensitivity. The frequency of staphylococcus multi-drugs resistance is rising as well in Asser region), involving variable drugs mode of actions; cell wall inhibitors, protein synthesis inhibitors and DNA gyrase inhibitors.

Rising of multidrug resistance could be attributed to genetic clone and the adherence of the pathogen to devices like ventilators and catheters .

REFERENCES RÉFÉRENCES REFERENCIAS

1. Otto, S.Q.a.M., "*Staphylococcus epidermidis* and other Coagulase-Negative Staphylococci". *Staphylococcus: Molecular Genetics*. Caister Academic Press;, 2008:.
2. Bacteria, *Bacteria Genomes -Staphylococcus epidermidis*. Karyn's Genomes.. EMBL-EBI.. , 2011
3. Otto M, "*Staphylococcus epidermidis* — the 'accidental' pathogen". *Nature Reviews Microbiology* 2009. 7(8): p. 555–567.
4. Francois, P. and a.S. J., "*Rapid Diagnosis and Typing of Staphylococcus aureus*". *Staphylococcus: Molecular Genetics*. .Caister Academic Press, 2008:.
5. Kayser, J.E. KB, and R. Zinkernagel, *Medical Microbiology* Thieme, 2005: p. 724.
6. van Leeuwen W SM, et al., *On the nature and use of randomly amplified DNA from Staphylococcus aureus*. *J Clin Microbiol.* , 1996 34(11): p. 2770-2777.
7. Siripornmongcolchai T, Chomvarin C, and e.a. Chaicumpar K, *Evaluation of different primers for detecting mecA gene by PCR in comparison with phenotypic methods for discrimination of methicillin-resistant Staphylococcus aureus*. . Southeast Asian J Trop Med Public Health., 2002. 33(4) : p. 758-63. .
8. Abd El Hafez, M., et al., *An outbreak of methicillin resistant Staphylococcus epidermidis among neonates in a hospital in Saudi Arabia*. *J Infect Dev Ctries*, 2011. 5(10): p. 692-9.
9. Brackman, G., et al., *Biofilm inhibitory and eradicating activity of wound care products against Staphylococcus aureus and Staphylococcus epidermidis biofilms in an in vitro chronic wound model*. *J Appl Microbiol*, 2013. 114(6): p. 1833-42.

10. Baillif, S., et al., *Staphylococcus epidermidis* biofilm formation and structural organization on different types of intraocular lenses under in vitro flow conditions. *Ophthalmic Res*, 2013. 50(2): p. 83-90.
11. Endocarditis", *Endocarditis*". Mayo Clinic. , 2011.
12. Bek-Thomson, M.e.a., "Acne is Not Associated with Yet-Uncultured Bacteria". *Journal of Clinical Microbiology*, 2008: . 46 (10): p. 3355–3360.
13. Pasko, C., et al., *Staph ID/R: a rapid method for determining staphylococcus species identity and detecting the mecA gene directly from positive blood culture*. *J Clin Microbiol*, 2012. 50(3): p. 810-7.
14. Donovan, S.T., et al., *Methicillin-resistant Staphylococcus aureus as a cause of neonatal suppurative parotitis: a report of two cases and review of the literature*. *Ear Nose Throat J*, 2013. 92(6): p. 269-71.
15. Crum-Cianflone, N.F., et al., *Association of methicillin-resistant Staphylococcus aureus (MRSA) colonization with high-risk sexual behaviors in persons infected with human immunodeficiency virus (HIV)*. *Medicine (Baltimore)*, 2011. 90(6): p. 379-89.
16. Cotter, J.J., et al., *Disinfection of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis biofilms using a remote non-thermal gas plasma*. *J Hosp Infect*, 2011. 78(3): p. 204-7.
17. Bassetti, M., et al., *Vancomycin susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia isolates in an Italian hospital*. *Int J Antimicrob Agents*, 2011. 38(5): p. 453-4.
18. Aiba, Y., et al., *Mutation of RNA polymerase beta-subunit gene promotes heterogeneous-to-homogeneous conversion of beta-lactam resistance in methicillin-resistant Staphylococcus aureus*. *Antimicrob Agents Chemother*, 2013. 57(10): p. 4861-71.
19. Liu, C., et al., *Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary*. *Clin Infect Dis*, 2011. 52(3): p. 285-92.
20. Nandwani, S., A. Pande, and M. Saluja, *A case of Staphylococcus toxic shock syndrome presenting with multiple pneumatoceles in the chest*. *Indian J Chest Dis Allied Sci*, 2013. 55(1): p. 45-7.
21. Abdalla, N., *Study on Antimicrobial Resistant in Saudi Arabia*. *Research Journal of Medical Sciences*, 2011. 5(2): p. 94-98.
22. Widerstrom, M., et al., *Coagulase-negative staphylococci: update on the molecular epidemiology and clinical presentation, with a focus on Staphylococcus epidermidis and Staphylococcus saprophyticus*. *Eur J Clin Microbiol Infect Dis*, 2012. 31(1): p. 7-20.
23. Geva, A., et al., *Spread of methicillin-resistant Staphylococcus aureus in a large tertiary NICU: network analysis*. *Pediatrics*, 2011. 128(5): p. e1173-80.
24. Kane, E. and G. Bretz, *Reduction in coagulase-negative staphylococcus infection rates in the NICU using evidence-based research*. *Neonatal Netw*, 2011. 30(3): p. 165-74.
25. Abdalla, N.M., *Evaluation of resistance of commonly used antibiotics on clinical case of Staphylococcus capitis from Assir region, Saudi Arabia*. *Indian J Med Sci*, 2011. 65(12): p. 547-51.
26. Alreshidi, M.A., et al., *Genetic variation among methicillin-resistant Staphylococcus aureus isolates from cancer patients in Saudi Arabia*. *Eur J Clin Microbiol Infect Dis*, 2013. 32(6): p. 755-61.
27. Hamid, M.E., et al., *Prevalence of Bacterial Pathogens in Aseer Region, Kingdom of Saudi Arabia: Emphasis on Antimicrobial Susceptibility of Staphylococcus aureus*. *Oman Med J*, 2011. 26(5): p. 368-70.
28. Toba, F.A., et al., *Role of biofilm in Staphylococcus aureus and Staphylococcus epidermidis ventricular assist device driveline infections*. *J Thorac Cardiovasc Surg*, 2011. 141(5): p. 1259-64.
29. Dumitrescu, O., et al., *Beta-lactams interfering with PBP1 induce Panton-Valentine leukocidin expression by triggering sarA and rot global regulators of Staphylococcus aureus*. *Antimicrob Agents Chemother*, 2011. 55(7): p. 3261-71.



This page is intentionally left blank



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY
Volume 14 Issue 2 Version 1.0 Year 2014
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Merkel Cell Carcinoma : An Indian Experience

By Dr. Biswanath Paul, Dr. Bhaskar Mitra, Dr. Mallika Pal,
Dr. Tarak Nath Saha & Dr. Ashok Maiti

Midnapore Medical College & Hospital, India

Abstract- Merkel cell carcinoma [MCC] is a rare neoplasm of skin with an aggressive behaviour and unfavourable prognosis. MCC mainly occurs in the elderly, in the sun exposed areas of skin. Indian's experiences regarding patients' profiles, clinical presentation, age of occurrence, pattern of tumour are very limited as well as challenging.

This retrospective study was performed, in a tertiary care hospital in Paschim Medinipur, West Bengal, India, reviewing the cases of five patients.

In our cases we try to elaborate data regarding the age of occurrences, presentation, and behaviour of tumour and prognosis of MCC.

The patients' profiles, clinical presentation, age of occurrence & the tumour characteristics including histopathological and immunohistochemical profiles are similar to the cases presented in other parts of world.

Keywords: merkel cell carcinoma, neuroendocrine tumour, skin tumour.

GJMR-C Classification : NLMC Code: QZ 365, WP 460



Strictly as per the compliance and regulations of:



© 2014. Dr. Biswanath Paul, Dr. Bhaskar Mitra, Dr. Mallika Pal, Dr. Tarak Nath Saha & Dr. Ashok Maiti. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Merkel Cell Carcinoma : An Indian Experience

Dr. Biswanath Paul ^α, Dr. Bhaskar Mitra ^σ, Dr. Mallika Pal ^ρ, Dr. Tarak Nath Saha ^ω & Dr. Ashok Maiti ^ϕ

Abstract- Merkel cell carcinoma [MCC] is a rare neoplasm of skin with an aggressive behaviour and unfavourable prognosis. MCC mainly occurs in the elderly, in the sun exposed areas of skin. Indian's experiences regarding patients' profiles, clinical presentation, age of occurrence, pattern of tumour are very limited as well as challenging.

This retrospective study was performed, in a tertiary care hospital in Paschim Medinipur, West Bengal, India, reviewing the cases of five patients.

In our cases we try to elaborate data regarding the age of occurrences, presentation, and behaviour of tumour and prognosis of MCC.

The patients' profiles, clinical presentation, age of occurrence & the tumour characteristics including histopathological and immunohistochemical profiles are similar to the cases presented in other parts of world.

Keywords: merkel cell carcinoma, neuroendocrine tumour, skin tumour.

I. INTRODUCTION

Merkel cell carcinoma(MCC) is a rare primary cutaneous neoplasm with epithelial and neuroendocrine differentiation and it has been first described by Toker in 1972¹ as the "trabecular carcinoma of the skin". This neoplasm arises from the neuronal crest cells- Merkel cells which is situated in the basal layer of the epidermis. Though the exact cause remains unknown, sunlight has been reported to be a major risk factor. Common associations include in situ or invasive squamous cell carcinoma, basal cell carcinoma indicating its origin from multipotent stem cells of ectodermal derivation. High occurrence of this tumour in organ transplant recipients and in immunocompromised patients indicates the role of immunosuppression in its etiology(2). The reported annual incidence of MCC ranges from 0.2 to 0.45 per 100000³. It is mainly a disease of the Caucasian race. The annual age-adjusted incidence of MCC is 0.23 per 100,000 for whites and 0.01 for blacks⁴. Age of occurrence in elderly with mean age at presentation being around 75 years⁵. Only a few cases reported before the age of 50, and are usually related to immunosuppression⁶. Many cases have been reported worldwide, majority of which are Caucasians, while Indian experience regarding incidence of MCC, clinical presentation, age of occurrence and pattern of tumour

Author^{α σ ρ ω}: Department of Pathology, Midnapore Medical College & Hospital, Paschim Medinipur, West-Bengal, India.
e-mail: bhaskarmitra12@gmail.com

Author^ϕ: Cancer Detection Centre Midnapore Medical College & Hospital, Paschim Medinipur West-Bengal, India.

are very limited. So in this article we tried to share our experience of such few rare occurrences in a tertiary care hospital of eastern India.

II. MATERIAL AND METHODS

These retrospective observations were performed in a tertiary care hospital in Paschim Medinipur, West Bengal, India between 2009 -2011. We included patients with a pathologic diagnosis of MCC coming from neighbouring rural areas to this hospital. Patient characteristics, clinical features of the lesion (i.e. site, size, tenderness, colour and growing time), stage at presentation, and clinician's impression at the time of biopsy were reviewed. Tissue specimens were obtained from the Department of Surgery, Midnapore Medical College, Paschim Medinipur, West Bengal. Table 1 & 2 represents the patients & tumour characteristics respectively. The tissue samples were routinely embedded in paraffin and processed at the Department of Pathology, Midnapore Medical College Hospital, stained with Haematoxylin and Eosin stain and immunohistochemically studied with CK-20, chromogranin, neuron specific enolase (NSE) and TTF-1 as markers to confirm the diagnosis.

Table 1 : Patient's characteristics

		Number of cases (%)
Age	< 50 years	1(20%)
	60- 70 years	4 (80%)
Sex	Male	3(60%)
	Female	2 (40%)
Race	Asian	5
Occupation	Farmer	5
Immunocompromised	Yes due to CLL	1
	No	4

Table 2 : Tumour characteristics

		Number of cases (%)
Site of tumour	Head & neck	2(40%)
	Upper limb	2(40%)
	Lower limb	1(20%)
Size of tumour	< 2 cm	3 (60%)
	>2 cm	2(40%)
Shape of tumour	Nodular	4 (80%)
	Ulcerative	1 (20%)
Lymph node involvement	Yes	2(40%)
	No	3(60%)

III. RESULT

Patient characteristics, as detailed in table no 1, shows that during the study period 5 patients were came with a skin lesion, among them one was younger than 50 year, and others were older than 60 year. There was a slight male predominance with a ratio of 1.5:1 (60% male and 40% female). In this study all patients were Asian and farmer with history of occupational sun exposure. One patient had history of immunosuppression due to pre-diagnosed CLL.

As mentioned in Table 2, most lesions appeared on sun-exposed skin. Most common site of the primary tumour was head & neck region (40%) and upper limbs (40%), followed by lower limbs (20%) (Fig-1). Size of the tumours were variable ranging from 1.5 cm to 4.6 cm. Primary tumour diameter of less than 2 cm was found in 3 cases and that of more than 2 cm in 2 cases. Four patients presented with a nodule covered by intact skin, while more advanced tumour form was found in one with ulcerating growth. The lesions were painless, firm, and non-tender. Regional lymph node metastasis found in two patients. Three patients of the group having no regional lymph node metastasis were clinically diagnosed as benign lesion. Other two patients

with lymph node enlargement were clinically suspected as malignant.

All patients were subjected to excision followed by histopathological examination. The prepared H&E stained slides exhibited diffuse pattern of infiltration of dermis by small round cells with an intact epidermis (Fig 2a, 2b & 2c), cells having scanty eosinophilic cytoplasm and round vesicular nuclei with fine granular chromatin (Fig 2d). In immunohistochemical examination, the tumor cells showed typical perinuclear dot like positivity for cytokeratin 20 (Fig- 3a), negative for TTF-1 (Fig- 3b), as well as immunoreactive for chromogranin (Fig- 3c) and NSE (Fig- 3d). On the basis of these histological and immunohistochemical features, diagnosis of Merkel Cell Tumor were established. Then additional excisions were performed to achieve margins 3 cm wide and 1–2 cm deep along with lymph node dissection. The patients were evaluated with a CT scan for staging. CT scan reports revealed regional lymph node metastasis in two patients having primaries more than 2 cm in size; others were negative for metastasis. All patients were treated with post-operative radiotherapy. The follow-up were done through CT scan. Two patients died 1 year later during the follow-up period.



Fig: 1a



Fig: 1b

Figure 1




Figure 2




Figure 3

IV. DISCUSSION

Merkel cell carcinoma is a rare neoplasm of skin with an aggressive behaviour and unfavourable prognosis⁷. Many reported cases found in literature are mainly in white⁴. Data regarding the occurrences, presentation, behaviour of tumour and prognosis is still limited in Indian subcontinent. In our study we found only five cases of MCC in three years of span (2009-2011). It is mainly a tumour of elderly⁵, few cases found before age of 50 years were associated with immunosuppression⁶. In our study, among five cases four (80%) were within age range of 60-80 years and one (20%) younger than 50 years, who had previously diagnosed CLL. According to Brenner et al incidence of CLL as second neoplasm is 15.9% & majority of this second neoplasm preceded the diagnosis of MCC⁸. Here the occurrence of MCC was slightly higher in male

with M:F ratio of 1.5:1, which also follows Heath et al study⁹. Constant sun light exposure is obvious in all patients as they all are farmer by occupation. Also they presented with tumours involving head & neck, upper limbs and lower limbs, supporting the possible contributory role of sun light in development of MCC, as shown by Miller & Rabkin in their study that incidence of MCC is increased with the exposure of solar UVB ray^{9,10}. Van Gele et al also shows a UV-B-induced C to T mutation in MCC cell line¹¹, suggesting that sun exposure plays a leading role in the pathogenesis of this tumour. However, this does not provide a satisfactory explanation, because MCC has been reported in non-sun exposed sites.

MCC usually presented as a non-tender nodular growth, sometimes as an ulcerated lesion⁷. Most of the tumours are approximately 2 to 4 cm in diameter¹². Clinically correct diagnosis is made rarely, because

these lesions can resemble many other tumours. The clinical differential diagnosis often includes basal cell carcinoma, squamous cell carcinoma, pyogenic granuloma, keratoacanthoma, amelanotic melanoma, adnexal tumor, clear cell acanthoma, lymphoma, and metastatic carcinoma¹³.

On gross examination it shows grey coloured cut surface¹⁴ (Fig-1). Microscopically tumour occurs in the dermis, sometimes in subcutaneous tissue with an intact overlying epidermis⁷, though epidermal involvement by the tumour is also reported previously¹⁵. Tumours are composed of small round cells arranged in diffuse and sometimes in trabecular pattern. The cells have scanty eosinophilic cytoplasm and round vesicular nuclei with fine granular chromatin & multiple nucleoli. Mitotic count is high^{16,17}. Immunohistochemically MCC are positive for low molecular weight keratin (CK20), chromogranin & neuron specific enolase^{7,18}. The CK20 shows typical perinuclear dot like positivity⁷. MCC are negative for TTF-1^{19, 20}. In our present study all cases show similar above mentioned histological & immunohistochemical features.

Different types of chromosomal abnormalities have been reported in this tumour. Trisomy of chromosome 6 & 1 are most typical^{21, 22, 23} along with partial & complete trisomy of chromosome 11^{24, 25}.

Due to rarity of the tumour there are multitudes of treatment protocols. The treatment depends on the stage of the tumour at the time of presentation. Patient with a localized tumour surgery with excision of 3 cm wide margins and 2 cm depth is considered as a gold standard method.^{26, 27} Postoperative radiotherapy in patients without lymph node metastasis is still controversial. But due to high rate of local relapse, 45-60 Gy^{26, 28} is used routinely to the area of lesion to decrease the local recurrence²⁹. The lymph node involvement is an important prognostic factor of this tumour. Its involvement decrease the survival rates from 88% to 50% and it is evident in 50% -70% of all patients within 2 years of diagnosis³⁰. So sentinel node biopsy³¹ and routine lymph node dissection^{27, 32} is strongly recommended along with postoperative radiotherapy in case of its metastasis³³. Other poor prognostic factors are tumour size >2 cm, male sex, age>60 years & immunosuppression^{26, 29, 32}.

V. CONCLUSION

We reported five cases of merkel cell carcinoma, arising in different parts of the body, from surrounding areas of Paschim Medinipur district in eastern India. Patients' profiles and tumour characteristics including histopathological findings & immunohistochemical patterns are similar to those presented in other parts of world. A strong clinical suspicion, clinicoradiological correlation and histopathological and immunohistochemical confirm-

ation are required for proper evaluation along with wide margin resection with or without postoperative radiotherapy & lymph node dissection.

VI. ACKNOWLEDGEMENT

The authors gratefully acknowledge the assistance of the laboratory staffs of the Department of Pathology, Midnapore Medical College and Hospital.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Toker C. Trabecular carcinoma of the skin. *Arch Dermatol* 1972, 105:107-110.
2. Ziprin P, Smith S, Salerno G, Rosin RD. Two cases of Merkel cell tumour arising in patients with chronic lymphocytic leukemia. *Br J Dermatol* 2000, 142(3):525-528.
3. Pan, D. Naryan, D. and Ariyan, S. (2002). "Merkel Cell Carcinoma: Five Case reports Using Sentinel Lymph Node Biopsy and Review of 110 New Cases." *Plastic and Reconstructive surgery* 110: 1259 - 1265.
4. Miller, R. W. and Rabkin, C. S. (1999). "Merkel cell carcinoma and melanoma: etiological similarities and differences." *Cancer Epidemiol Biomarkers Prev* 8(2): 153-8.
5. Savage, P., Constenla, D., Fisher, C., Thomas, J. M. and Gore, M. E. (1997). "The natural history and management of Merkel cell carcinoma of the skin: a review of 22 patients treated at the Royal Marsden Hospital." *Clin Oncol (R Coll Radiol)* 9(3): 164-7.
6. Penn, I. and First, M. R. (1999). "Merkel's cell carcinoma in organ recipients: report of 41 cases." *Transplantation* 68(11): 1717-21.
7. Rosai J: *Rosai and Ackerman's Surgical Pathology*. Mosby 9th edition. 2004, 1:177 179.
8. Brenner, B. Sulken, A. Rakowsky, E. Feinmesser, M. et al. (2001). "Second neoplasm in patients with merkel cell carcinoma." *Cancer* 91(7): 1358-62.
9. Heath. M, Jaimes. N, Lemos. B, Mostaghim. A. et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. *J AM ACAD DERMATOL* 58(3): 375-81.
10. Miller, R. W. and Rabkin, C. S. (1999). "Merkel cell carcinoma and melanoma: etiological similarities and differences." *Cancer Epidemiol Biomarkers Prev* 8(2): 153-8.
11. Van Gele M, Kaghad M, Leonard JH, et al. Mutation analysis of P73 and TP53 in Merkel cell carcinoma. *Br J Cancer*. 2000;82:823-826.
12. Haag ML, Glass LF, Fenske NA. Merkel cell carcinoma: diagnosis and treatment. *Dermatol Surg*. 1995;21:669-683.
13. O'Connor WJ, Brodland DG. Merkel cell carcinoma. *Dermatol Surg*. 1996;22:262-267.

14. Silva EG, Mackay B, Goepfert H, et al. Endocrine carcinoma of the skin (Merkel cell carcinoma). *Pathol Annu.* 1984;19:1-30.
15. Smith. PD, Patterson. JW. Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin) *Am J Clin Pathol* 2001;115 (Suppl 1):S68-S78.
16. Sidhu GS, Feiner TJ, Mullins JD, Schaeffler K, Schultenhover SJ: Merkel cell Neoplasms. Histology, electron microscopy, biology and histogenesis. *Am J Dermatopathol* 1980, 2:101-119.
17. Walsh NM: Primary neuroendocrine (Merkel cell) carcinoma of the skin. Morphologic diversity and implications thereof. *Hum Pathol* 2001, 32:680-689.
18. Hofler H, kerl H, Lackinger E, Helleis G, Denk H. The intermediate filament cytoskeleton of cutaneous neuroendocrine carcinoma (merkel cell tumour). Immunohistochemical and biochemical analysis. *Virchows Arch [A]* 1985, 406: 339-350.
19. Byrd-Gloster AL, Khor A, Glass LF, et al. Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. *Hum Pathol.* 2000;31:58-62.
20. Hanly AJ, Elgart GW, Jorda M, et al. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates Merkel cell carcinoma from small cell carcinoma of lung. *J Cutan Pathol.* 2000;27:118-120.
21. Larsimont, D. and Verhest, A. (1996). "Chromosome 6 trisomy as sole anomaly in a primary Merkel cell carcinoma." *Virchows Arch* 428(4-5): 305-9.
22. Gancberg, D. Feoli, F. Hamels, J. et al. (2000). "Trisomy 6 in Merkel cell carcinoma: a recurrent chromosomal aberration." *Histopathology* 37(5): 445-51.
23. Vortmeyer, A. O., Merino, M. J., Boni, R., Liotta, L. A., Cavazzana, A. and Zhuang, Z. (1998). "Genetic changes associated with primary Merkel cell carcinoma." *Am J Clin Pathol* 109(5): 565-70.
24. Leonard, J. H., Leonard, P. and Kearsley, J. H. (1993). "Chromosomes 1, 11, and 13 are frequently involved in karyotypic abnormalities in metastatic Merkel cell carcinoma." *Cancer Genet Cytogenet* 67(1): 65-70.
25. Amo-Takyi, B. K., Tietze, L., Tory, K., et al. (1999). "Diagnostic relevance of chromosomal in-situ hybridization in Merkel cell carcinoma: targeted interphase cytogenetic tumour analyses." *Histopathology* 34(2): 163-9.
26. Pectasides D, Pectasides M, Economopoulos T: Merkel cell cancer of the skin. *Ann Oncol* 2006, 24:1489-1495.
27. Eng TY, Boersma MG, Fuller CD, Cavanaugh SX, Valenzuela F, Herman TS: Treatment of merkel cell carcinoma. *Am J Clin Oncol* 2004, 27(5):510-515.
28. Boyse K, Foley EH, Bradley V, Scarborough D: Merkel cell carcinoma: a case report with treatment summary and updates. *Cutis* 2004, 74:350-356.
29. Senchenkov A, Barnes SA, Moran SL: Predictors of survival and recurrence in the surgical treatment of merkel cell carcinoma of the extremities. *J Surg Oncol* 2007, 1;95(3):229-234.
30. Mehrany K, Otley CC, Weenig RH, Phillips PK, Roenigk RK, Nguyen TH: A meta-analysis of the prognostic significance of sentinel lymph node status in Merkel cell carcinoma. *Dermatol Surg* 2002, 28(2):113-117.
31. Bichakjian CK, Lowe L, Lao CD, Sandler HM, Bradford CR, Johnson TM, Wong SL: Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. *Cancer* 2007, 110:1-12.
32. Dinh V, Feun L, Elgart G, Savaraj N: Merkel cell carcinomas. *Hematol Oncol Clin North Am* 2007, 21:527-544.
33. Papamichail M, Nikolaidis I, Nikolaidis N, Glava C, Lentzas I, Marmagkiolis K, Karassavsa K, Digalakis M : Merkel cell carcinoma of the upper extremity: Case report and an update. *World Journal of Surgical Oncology* 2008, 6:32.





This page is intentionally left blank



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY
Volume 14 Issue 2 Version 1.0 Year 2014
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Opportunistic Infections Vs Immune Suppression Among HIV Seropositive Individuals in East Godavari District, Andhra Pradesh

By Ankam SS Rajendra Babu, T.Jaya Chandra, Budida Ramachandramouli
& Dr. R.Lakshmi Kumari

GSL Medical College, Rajahmundry, India

Abstract- Aim: To detect the opportunistic infections (OIs) and level of immune suppression in HIV sero positive patients in East Godavari district, Andhra Pradesh.

Material and methods: Study was conducted in the department of Microbiology, Rangaraya Medical College, Kakinada, referral center for HIV diagnosis and treatment by NACO. Study period 27 months, January 2011 to April 2013. Clinical specimen include stool, sputum, CSF, lymph node aspiration, swabs from oral cavity, blood were collected from 178 confirmed HIV seropositive individuals.

Results: Male female ratio was 1.41: 1. More number of HIV positive cases were seen in the age group of 31- 40 years (34%) and fever (72%) is the common clinical symptom. Mycobacterium tuberculosis (51%) was most commonly isolated pathogen, followed by Candida (39%), Cryptosporidium parvum (24%) with mean CD4 counts 231, 160 and 72 cells / μ l respectively. Poly microbial infections were seen in 34% of the study volunteers.

Keywords: HIV, opportunistic infections (OIs), mycobacterium, candida.

GJMR-C Classification : NLMC Code: WC 140



Strictly as per the compliance and regulations of:



© 2014. Ankam SS Rajendra Babu, T.Jaya Chandra, Budida Ramachandramouli & Dr. R.Lakshmi Kumari. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Opportunistic Infections Vs Immune Suppression Among HIV Seropositive Individuals in East Godavari District, Andhra Pradesh

Ankam SS Rajendra Babu ^α, T.Jaya Chandra ^σ, Budida Ramachandramouli ^ρ & Dr. R.Lakshmi Kumari ^ω

Abstract- Aim: To detect the opportunistic infections (OIs) and level of immune suppression in HIV sero positive patients in East Godavari district, Andhra Pradesh.

Material and methods: Study was conducted in the department of Microbiology, Rangaraya Medical College, Kakinada, referral center for HIV diagnosis and treatment by NACO. Study period 27 months, January 2011 to April 2013. Clinical specimen include stool, sputum, CSF, lymph node aspiration, swabs from oral cavity, blood were collected from 178 confirmed HIV seropositive individuals.

Results: Male female ratio was 1.41: 1. More number of HIV positive cases were seen in the age group of 31- 40 years (34%) and fever (72%) is the common clinical symptom. *Mycobacterium tuberculosis* (51%) was most commonly isolated pathogen, followed by *Candida* (39%), *Cryptosporidium parvum* (24%) with mean CD4 counts 231, 160 and 72 cells / μ l respectively. Poly microbial infections were seen in 34% of the study volunteers.

Conclusion: OIs are the major cause of mortality and morbidity in HIV positive patients. So early and correct diagnosis of OIs is required for proper disease management.

Keywords: HIV, opportunistic infections (OIs), *mycobacterium*, *candida*.

I. INTRODUCTION

The unique pathogenesis of HIV virus and drop in CD4 count are the two aspects responsible for the emergence of opportunistic infections (OIs) in HIV patients ¹. Due to decrease in immunity, people with HIV are prone for OIs and these infections are recognized as common complication ^{2, 3, 4}. OIs are major cause of morbidity and mortality in HIV patients ^{5, 6}.

In the HIV positive individuals the incidence of OIs is reduced dramatically with introduction of Anti retroviral treatment (ART). But ART is not available to all in the resource limiting countries like India ⁷. AIDS is the most important problem in 20th century ³ and leading

cause of death. So care has to be taken to prevent and treat the OIs.

Various microorganisms cause OIs in HIV patients. As per the available literature tuberculosis, candidiasis, cryptosporidium diarrhoea, cryptococcal meningitis, pneumocystis carinii pneumonia are some of the common OIs in the HIV sero positive individuals⁸. The frequency of OIs may not be same in all countries and differ within the country. In resource limited, developing and high HIV burden countries like India the incidence and severity of OIs is high. But the literature which is available in this regard is limited especially with the correlation of immune suppression.

AIDS caused by HIV may not be curable. But the OIs can be treated. Hence identification of OIs causing pathogens is very important and essential in HIV patients for disease management. This not only prolongs the life of HIV individuals but also improve the quality of life.

We conducted a study to identify OIs causing microorganisms in HIV patients of East Godavari district in relation to the immune status.

II. MATERIAL AND METHODS

Study was conducted in the department of Microbiology, Rangaraya Medical College (RMC), Kakinada, for 27 months, study period January 2011 to April 2013. RMC, a National AIDS Control Organization (NACO) referral center for HIV diagnosis and treatment in East Godavari district, Andhra Pradesh. So HIV seropositive patients from different parts of district were included in the study.

Study population consists of HIV positive patients, both genders. Informed consent was taken from all the individuals in the presence of witness if required i.e. in case of minors and illiterates. Based on clinical condition and patient status various clinical samples were collected. This include stool, sputum, CSF, lymph node aspiration, swabs from oral cavity, blood.

Stool samples were collected in a wide mouth bottle. All the volunteers were instructed clearly that stool sample should not get contaminated with urine. Trophozoites, cysts, larva and helminthic ovum were identified in the stool samples by observing saline,

Author α: Department of Microbiology, Rajiv Gandhi Institute of Management and Sciences, Kakinada.

Author σ: Department of Microbiology, GSL Medical College, Rajahmundry: 533296.

Author ρ: Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany.
e-mail: chanduthgreat@rediffmail.com

Author ω: Department of Microbiology, Siddardha Medical College, Vijayawada.

lugols iodine mount and LPCB mount^{9, 10}. In addition stool smears were stained by modified ZN staining¹⁰ to identify protozoan parasites like *Cryptosporidium parvum*, *Isospora belli*, Cyclospora. The predominant bacteria cause enteric infection, Salmonella, Shigella, *Vibrio cholerae* were isolated and identified by inoculating stool sample on MacConkey agar, selective media i.e. XLD / DCA/ TCBS and growth is identified by various biochemical reactions as per the standard protocols^{11, 12}.

Sputum samples were collected as per Jaya Chandra et al¹³ i.e three deep breaths followed by a deep cough. Minimum 5ml of sputum sample was collected. Immediately after collection, smear was prepared and stained by Ziehl Neelsen staining as per Revised National Tuberculosis Control Programme (RNTCP) guidelines¹⁴. After smear preparation, sputum samples were concentrated and decontaminated by NALC NaOH method¹⁵ and the deposit was inoculated in 2 sets of LJ media and incubated at 37°C. LJ culture reading was done as per RNTCP guidelines¹⁶.

Oral swabs were inoculated on Sabourds Dextrose Agar (SDA) to identify candida which is the causative agent of oral candidiasis. For speciation, chlamyospore formation, germ tube test was done and the isolated candida was also inoculated on chrome agar¹⁷.

CSF samples were collected from meningitis patients. Gram stained CSF smears were observed to identify the bacteria or fungal causative agents and India ink smears to identify cryptococcus capsule. CSF samples were inoculated on Chocolate agar, MacConkey agar, SDA and processed as per the standard protocol^{10, 11}.

In addition to clinical correlation, blood samples were tested for ELISA to identify Herpes simplex virus, Cytomegalo virus infections. CD4 counts were estimated by using BD FACS caliber machine as per the NACO guidelines.

III. RESULTS

In the study male female ratio was 1.41: 1. More number of HIV positive cases were seen in the age group of 31- 40 years (Table: 1). Fever (72%) was the most common symptom followed by weight loss (69%) and chronic cough (44%) (Table: 2). *Mycobacterium tuberculosis* (51%) was the most commonly isolated pathogen, followed by Candida (39%), *Cryptosporidium parvum* (24%) (Table: 3) with mean CD4 counts 231, 160, 72 cells / μ l. Poly microbial infections were seen in 34% of the volunteers (Table: 4), common in the patients with low CD4 counts. Figure shows the OIs in relation with immune stautus.

IV. DISCUSSION

AIDS the only cause of HIV is the burning health issues of developing countries like India. India accounts

for 1% of global burden. In AIDS patient's death is mainly due to OIs not by HIV. The important observation in our study is that OIs are seen in all the study subjects. So prevalence of OIs is 100%.

In our study majority of HIV positive cases were seen in the age group 31 – 40 years, 34% (60 out of 178 cases). Madhkar SS et al⁴ and Patel SD et al¹⁸ reported 53.3%, 52% HIV positivity in 31 – 40 years age group.

The present study showed that fever (72%) is the most commonly presenting symptom, followed by chronic cough (49%), chronic diarrhoea (48%), oral thrush (34%) and lymphadenopathy (25%). Most of the study subjects were presented with mixed symptoms. Findings of our study were very close with Patel SD¹⁸, Gupta V et al¹⁹, SK Sharma et al²⁰ showed fever is the most common complaint found in 64%, 51% and 70.4% followed by weight loss in 47%, 43% and 62.5% respectively. But weight loss (47.8%) is the common complication followed by PUO (36%) and chronic cough (33%), chronic diarrhoea (32.3%) as per Deorukhkar et al³ report.

In the current study out of 178 HIV positive cases 98 patients expressed the promiscuous behaviour and all are heterosexuals with more than one sexual partner. Among these subjects HIV seropositivity was 84%. The available literature is also stated that heterosexual route is the commonest route of HIV transmission^{4, 21, 22, 23}.

This study revealed that Mycobacterium is the most common OIs causing agent in HIV patients, Mycobacterium isolation was 51%, followed by Candida (39%) and *Cryptosporidium parvum* (24%). Our findings were comparable with previous studies. In the available literature Mycobacterium was isolated in 50%, 47%, 56%, 47%, 57% and 59% respectively in Biswas Jyotir may et al²⁴, Vajapayee M et al²⁵, Singh A et al²⁶, Sanjeev Sinha et al²⁷, Nilanjan Chakraborty et al² and Madkar SS et al⁴. In the current study both pulmonary tuberculosis (PT) and extra PT forms were seen (61, 11 cases) and mean CD4 count was 231 cells/ μ l. As per Moore et al²⁸ one of the earlier studies, the mean CD4 count was 261 cells / μ l in HIV positive patients with PT as OI and the reference range of CD4 counts were 250 to 500 cells / μ l according to Crowe et al²⁹ (Table: 5).

Candida infection is second (39%) common next to Mycobacterium. This is confirmed with the studies of Patel SD⁵ & Madhkar SS⁴, reported candidiasis in 33% and 37.6% HIV positive patients respectively. *Cryptosporidium parvum* is the third (24%) common identified pathogen and very common diarrhoea causing agent. As per the Kulkarni et al³⁰ study 12% *Cryptosporidium parvum* were isolated in HIV positive patients.

The very important aspect of our study is correlation between CD4 counts and OIs. Increased incidence of OIs was seen in individuals with low CD4 counts. OIs rate was very high (58%) when the CD4

counts were < 200 cells / μ l. As the CD4 count increases the incidence of OIs is decreased. The rate of OIs were 41% when CD4 counts were 200-500 cells / μ l and it was just 1% when the CD4 counts were > 500 cells / μ l. The reason is very clear, as the CD4 cell count is decreased, the individual may prone to other infections due to lowering of immune system³¹

can increase. Tuberculosis is the common OI followed by candidiasis, cryptosporidium diarrhoea. Diagnosis of OIs may not only decrease the mortality in HIV patients, but also increase the quality of life. Hence the diagnosis of OIs should be given prime importance in HIV sero positive patients.

V. CONCLUSION

Findings of our study showed that OIs are very common in HIV patients. As immunity decreases, OIs

Table 1 : Age wise distribution of study population

Age	1-10	11-20	21-30	31-40	41-50	51-60	61-70
HIV cases (%)	3 (1.7)	3 (1.7)	57 (32)	60 (34)	36 (20)	13 (7.3)	6 (3.4)

Table 2 : Different clinical symptoms of study population

Symptom	%
Fever	72
Weight loss	69
Chronic cough	49
Chronic diarrhoea	48
Oral thrush	34
Lymphadenopathy	25

Table 3 : Various OIs causing microorganisms in the study population

S.No	OIs	Number	Mean CD4 count in cells / μ l
1	Bacteria	98	341
	Mycobacterium tuberculosis	91 (51)	231
	Salmonella	2 (1.1)	293
	Pseudomonas aeruginosa	3 (1.7)	280
	Vibrio cholerae	2 (1.1)	560
2	Fungi	73	143
	Candida	69 (39)	160
	Cryptococcus neoformans	4 (2.5)	127
3	Parasites	49	107
	Cryptosporidium parvum	42 (24)	72
	Isospora belli	2 (1.1)	117
	Cyclospora	2 (1.1)	110
	Toxoplasma belli	3 (1.7)	130
4	Viruses	17	93
	Herpes simplex virus	9 (5)	110
	Cytomegalo virus	8 (4.5)	76

Table 4 : Mixed OIs in the study group (n= 178)

OIs	Number
Tuberculosis, Candida	14
Tuberculosis, Cryptococcus	08
Tuberculosis, cryptosporidium, Candida	07
Tuberculosis, Pneumocystis pneumoniae	04
Candida, cryptosporidium	12
Candida, Tuberculosis, Salmonella	7
Candida, Pseudomonas	7
Cryptosporidium, HSV	1

Table 5 : Comparison of CD 4 counts

OIs	CD4 count in cells / μ l		
	Present study	Moore et al ²⁸	Crowe et al ²⁹
Tuberculosis	231	261	250-500
Candidiasis	160	-	250-500
Cryptosporidium diarrhoea	72	28	150-200
Crptococcal meningitis	127	63	75-125
Toxopalsma	130	44	75
HSV	110	195	75
CMV	76	37	50




Figure showing OIs in relation with immune status

REFERENCES RÉFÉRENCES REFERENCIAS

- Rewari BB (Ed.) Virology and Immunopathology of HIV/ AIDS. Chapter 5. In: Specialists training and reference module. State Pram (Delhi) National AIDS Control Organization (New Delhi): 34-48.
- Nilanjan Chakraborty, Anirban Mukherjee, Santanu Santra, Rathindra Nath Sarkar, Dipanjan Banerjee, Shubhashish Kamal Guha, Sekhar Chakraborty and Sujit Kumar Bhattacharyya. Current Trends of Opportunistic Infections among HIV-Seropositive Patients from Eastern India, 2008:Jpn. J. Infect. Dis., 61; 49-53.
- Sachin C Deorukhkar and Santosh Saini. Opportunistic infections in human immunodeficiency virus (HIV) infected patients from rural tertiary care hospital of western Maharashtra. International Journal of Biomedical and Advance Research 2012; 3(12): 908-911.
- Madkar SS, Vankudre AJ, Neilekar SL. Spectrum of opportunistic infections in HIV AIDS patients. Indian J of Community Health 2012; 24 (3): 184-187.
- Moore, R.D. and Chassion, R.E. (1996): Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann. Intern. Med.124, 633-642.
- Finkelstein, D.M., Williams, P.I., Molenbergs, G., et al. (1996): Patterns of opportunistic infections in patients with HIV-infection. J. Acquir.Immune Defic. Syndr. Hum. Retrovirol., 12, 38-45.
- Kanabus, A., Fredriksson-Bass, J. and Noble, R. (2006): HIV-related opportunistic infections: prevention and treatment. AIDS-Care-Watch, 3, 1-11.
- Manual on laboratory diagnosis of common oppourtunistic infections associated with HIV? AIDS. Baveja UK, Sokhe J, editors. National Institute of Communicable Diseases and National AIDS Control Organization. Feb 2001.
- District laboratory practice in tropical countries. Monica cheesbrough 1998; Part 1: 196.
- Text book of medical Parasitology, Subhash Chandra Parija, 4th edition. All India publishers and distributors.2013: 335.
- Bailey & Scotts Diagnostic Microbiology. Betty A Forbes, Daniel F Sahn Alices weissfeld. 12th edition. Mosby Elsevier publisher 2007.
- Mackie & McCartney practical Medical Microbiology 14th Edition. Chursh Livingstone publisher, 1999.
- Same day sputum smear microscopy with prolonged primary staining step in a microscopy

- center at Rajahmundry, 2014; Indian J of Med Microb. (Press)
14. RNTCP Central TB Division. Manual for Laboratory Technicians. New Delhi, India: Directorate General of Health Services, Ministry of Health and Family Welfare, 1998. (<http://www.tbcindia.org/LABM-ANUAL.pdf>).
 15. T.Jaya Chandra, PA Rao, G.Srinivas, NVN Moorthy, PVP Rao. Role of Fiberoptic Bronchoscopy in smear negative and suspect cases of pulmonary tuberculosis 2006. NTI Bulletin, 42/1&2, 12-14.
 16. RNTCP Manual for Mycobacterium tuberculosis culture and drug susceptibility. Directorate General of Health Services, Ministry of Health and Family Welfare, New Delhi, India.
 17. Text book of Medical Mycology, Jagadish Chander 2nd edition; Mehta publisher, India: 2002.
 18. Patel SD, Kinariwala DM, Javadekar TB. Clinico-microbiological study of opportunistic infections in HIV seropositive patients. Indian J sex Transm Dis 2011; 32: 90-3.
 19. Gupta V, Singla N, Lehl S S, Chandler J. Clinico epidemiological profile of HIV infection over a period of six years in a North Indian tertiary care hospital. IJMM 2007; 25(2): 171.
 20. Sharma SK, Kadiravan T, Banga A et al. Spectrum of clinical disease in a series of 135 hospitalized HIV infected patients from North India. BMC infect. Dis. 2004; 4: 52.
 21. Kumaraswamy N, Solomon S, Jayaker Paul SA et al. Spectrum of opportunistic infections among AIDS patients in Tamil Nadu, India. Int J STD AIDS. 1995; 6: 447-449.
 22. Uzgare R. Mode of transmission of HIV in Mumbai (India) as per data collected in a private HIV/AIDS clinic. Int Conf AIDS. 2000 Jul 9-14; 13: abstract no.
 23. Kothari K, Goyal S. Clinical profile of AIDS. JAPI. 2001 Apr; 49: 435-8.
 24. Jyotirmay B, Amala J, Raizadaseemant et al. Ophthalmic manifestations of human immunodeficiency virus (HIV) Infection in India. Indian J Ophthalmology. 1999; 47: 87- 93.
 25. Vajpayee M, Kanswal S, Seth P, Wig N. Spectrum of opportunistic infections and profile of CD4+ counts among AIDS patients in North India. 2003 oct; 31 (5): 336-40.
 26. Singh A, Bairy I, Shivananda PG. Spectrum of opportunistic infections in AIDS cases. Indian J. Med science. 2003; 57 (1): 16-21.
 27. Sinha S, Guleria R. Spectrum of Pulmonary infections in HIV positive patients: Indian scenario. HIV Related lung Disease. October 27, 2004; Ref No. 109.
 28. Moore D, Chaisson RE (1996). Natural history of opportunistic disease in an HIV infected urban clinical cohort. *Annals of Internal Medicine* 124 633-642.
 29. Crowe SM, Carlin JB, Stewart KL, Lucas CR and Hoy JF (1991). Predictive value of CD4 lymphocytes numbers for the development of opportunistic infection and malignancies in HIV - infected patients. *Journal of Acquired Immuno Deficiency Syndrome* 4(8) 770-776.
 30. S.V. Kulkarni, R. Kairon, S.S. Sane, P.S. Padmawar, V.A. Kale, M.R. Thakar S.M. Mehendale & A.R. Risbud. Opportunistic parasitic infections in HIV/AIDS patients presenting with diarrhoea by the level of immunosuppression. Indian J Med Res 130, 2009; 130: 63-66.
 31. A Talib, V.H., Khurana, S.K., Pandey, J., et al. (1993): Current concepts: tuberculosis and HIV infection. Indian J. Pathol. Microbiol., 36, 503- 511.





This page is intentionally left blank



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY
Volume 14 Issue 2 Version 1.0 Year 2014
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Fatal Pulmonary Infection by a Multi-Resistant Strain of C. Laurentii in a Patient with Active Pulmonary Tuberculosis

By Aikaterini Marini, Alexios S. Antonopoulos, Claudia Lakoniti,
Evangelia Kouskouni & Konstantinos Gerolymatos

Aretaieion University Hospital, Greece

Abstract- We report the first case of concomitant C. laurentii and M. tuberculosis pulmonary infection in a non-immunocompromised patient caused by a multiresistant C. laurentii strain and the fourth reported case of C. laurentii pulmonary infection up to now. We review the literature regarding C. laurentii pulmonary infections as well as its treatment.

Keywords: *cryptococcus; tuberculosis; pulmonary infection; non-neoformans.*

GJMR-C Classification : *NLMC Code: WC 302, WF 300*



Strictly as per the compliance and regulations of:



© 2014. Aikaterini Marini, Alexios S. Antonopoulos, Claudia Lakoniti, Evangelia Kouskouni & Konstantinos Gerolymatos. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Fatal Pulmonary Infection by a Multi-Resistant Strain of *C. Laurentii* in a Patient with Active Pulmonary Tuberculosis

Aikaterini Marini ^α, Alexios S. Antonopoulos ^σ, Claudia Lakoniti ^ρ, Evangelia Kouskouni ^ω, & Konstantinos Gerolymatos [¥]

Abstract- We report the first case of concomitant *C. laurentii* and *M. tuberculosis* pulmonary infection in a non-immunocompromised patient caused by a multiresistant *C. laurentii* strain and the fourth reported case of *C. laurentii* pulmonary infection up to now. We review the literature regarding *C. laurentii* pulmonary infections as well as its treatment.

Keywords: *cryptococcus*; *tuberculosis*; *pulmonary infection*; *non-neoformans*.

I. INTRODUCTION

Our knowledge regarding non-neoformans cryptococcal infections has dramatically changed over the last years. While non-neoformans cryptococci had been previously considered as simple saprophytes, we now know that such cryptococci can be occasional pathogens, responsible for serious infections. *C. laurentii* together with *C. albidus* account for more than 80% of non-neoformans cryptococcal infections [1]. To our knowledge this is the fourth case of human *C. laurentii* lung infection and the first report of tuberculosis and *C. laurentii* co-infection of in a non-immunocompromised patient.

II. CASE REPORT

An ex-tanner, 83-year-old man presented to our emergency department with a 2-week history of weakness, chills, dyspnea, productive cough, haemoptysis and fever up to 39.5°C. He had a history of arterial hypertension, COPD, chronic atrial fibrillation and had undergone a surgery for an in-situ large intestine tumor removal 6 years ago. Physical examination revealed respiratory distress (35 breaths / min), with ample crackles and wheezes on auscultation of both lungs, while chest x-ray revealed signs of left-upper lobe pulmonary infiltration. The patient was hemodynamically stable, however his arterial blood gases indicated mild hypoxemia (pO₂=62mmHg, pCO₂=42mmHg, SaO₂=

89%). The initial laboratory tests revealed an acute inflammatory status with leukocytosis (WBC=15390/μL, Neutrophiles=13670/μL), a three-digit erythrocytes sedimentation rate (ESR=119mm/h) and highly elevated C-reactive protein (CRP=292 mg/L). There were no laboratory findings of renal / liver impairment or electrolytes' abnormalities. Blood, urine and sputum cultures were obtained and a tuberculin test was performed. He was immediately treated with ceftriaxone (2g/day), bronchodilators and nasal oxygen as a possible lung infection.

The combination of positive tuberculin test (15mm) and the radiologic and clinical features indicated a high risk of tuberculosis infection (figure 1A). Chest computed tomography reinforced our initial suspicion of active pulmonary tuberculosis by revealing a cavitated opaque lesion of the left upper lobe, as well as bronchopulmonary infiltrations of the lower lobes in both lungs and the reed (figure 1B). On this basis anti-tuberculosis treatment was initiated (rifampin 600mg/day, isoniazid 300/day, ethambutol 2g/day and pyrazinamide 2g/day). The patient remained nonfebrile for the next 9 days and the clinical and laboratory findings were ameliorated (WBC=7340/μL, Neutrophiles=6010/μL, CRP=94.5mg/L, ESR=95 mm/h). Meanwhile two samples of blood and sputum cultures were obtained.

However, during the following days the patient's clinical state deteriorated, manifesting marked respiratory distress, tachypnea, fever accompanied with chills (up to 39.0°C) and lethargic mental status. Moreover there was a simultaneous alteration in laboratory findings (CRP=170mg/L, ESR=102mm/h). Blood and urine cultures were negative, while sputum cultures' analysis revealed *M. tuberculosis* suggesting active pulmonary tuberculosis. Furthermore, sensitive strains of *Klebsiella pneumonia* and *Citrobacter freundii* were also isolated in sputums as well as a rare strain of *Cryptococcus*, identified as *C. laurentii*. These findings suggested co-infection of the underlying pulmonary tuberculosis with a very rare and highly resistant type of non-neoformans *Cryptococcus*. For the newly isolated bacterial strains, ciprofloxacin (400mg x 2) was added based on the antibiogram's results. Importantly, the

Author ^{α σ ρ ¥}: Internal Medicine Department, IKA Hospital, Melissia, Greece. e-mail: antonopoulosal@yahoo.gr

Author ^ω: Department of Microbiology, Aretaieion University Hospital, Athens, Greece.

identified *C. laurentii* strain was multi-drug resistant to all known antifungal agents (amphotericin B: MIC>16000 µg/mL, fluconazole: MIC>129000 µg/mL, itraconazole: MIC>4000 µg/mL, voriconazole: MIC>8000 µg/mL). Given the above results, empiric antifungal treatment with liposomal amphotericin B (5mg/kg) and caspofungin (70 mg on the first day and 50mg/day subsequently) was initiated in addition to the anti-TB drugs. The aforementioned multidrug resistance of the isolated *Cryptococcus* strain was also confirmed by the second sputum culture analysis. A microscope image of the *C. laurentii* strain was also taken and is depicted in figure 2.

Despite treatment, the patient remained lethargic and febrile with deteriorating vital signs. A second CT scan depicted the presence of liquid in pre-existing pulmonary cavity and "ground glass" sign in the right upper lobe (figure 1C). No abnormal findings were observed in the brain and abdomen CT scan. Ultimately the active pulmonary disease led to respiratory failure and death after 23 days of hospitalization.

III. DISCUSSION

Cryptococcus yeast is responsible for a series of very rare and life-threatening fungal infections in immunocompromised patients [2,3]. Cryptococcal infections are usually attributed to neoformans species, distributed in the air, soil, animal and plant organic residues [4]. *C. laurentii* along with *C. uniguttulatus*, *C. albidus*, *C. curvatus* and *C. humicolus* belong to non-neoformans cryptococci. *C. laurentii* and *C. albidus* are responsible for 80% of the non-neoformans infections [1]. Neoformans and non-neoformans species differ in capsule formation, melanin growth and antifungal resistance but their distinct classification remains a matter of debate.

Non-neoformans cryptococci were thought to be saprophytic and nonpathogenic to humans but incidence rates have importantly increased nowadays [1, 5, 6]. Interestingly, there are only 20 cases of *C. laurentii* human infections and only 3 affecting the lungs in immunosuppressed subjects [3, 6-9]. The yeast has been detected in normal skin, air, water, wood, soil, pigeon excrements, cheese, fruits, pork products, bean, wine and milk of suffering from mastitis cows [10]. There have been no previous reports of *C. laurentii* lung infection in a non-immunocompromised subject neither of a co-infection with *M. tuberculosis*. Thus, the present case is of high clinical interest since we report a unique so far concomitant lung infection of *C. laurentii* and *M. tuberculosis* in a healthy subject.

Predisposing factors to *C. laurentii* infection are the presence of invasive devices (e.g. intravenous catheters, parenteral nutrition), the use of broad spectrum antibiotics, impaired cell-mediated immunity, leukemia, cancer, diabetes mellitus, HIV, prematurity,

neutropenia, lymphopenia, immunosuppressive drug use and organ transplantation [1]. Extremely rare cases of "idiopathic CD4 deficiency" and congenital immunodeficiency have been also regarded as responsible for such infections. Our patient had no known defense impairment but he was diabetic and during his hospitalization he was treated with broad spectrum antibiotics. Furthermore, he carried central intravenous catheters for parenteral nutrition purposes.

Infection usually is acquired via the respiratory routes, alimentary tract and injured skin. *C. laurentii* may cause pneumonia, meningitis (2-9%), peritonitis, cutaneous infection, eye infection, invasive disease or fungemia. Fungemia of *C. laurentii* occurs mainly in cancer patients, neonates or as a complication of immunosuppressive therapy [1,11].

Pulmonary infection of *C. laurentii* can present as pneumonia, lung abscess or empyema [1, 8]. Typical radiographic findings include opaque or cavitated lesions, hilar enlargement, pleural fluid or an ARDS like pattern [1]. In our case, the chest radiography and a chest CT scan revealed a cavitated lesion with liquid levels and a typical pattern of pneumonia. Furthermore, the yeast has been previously isolated from sputum, pleural or abscess fluid and bronchial swab material [1]. Thus, its identification in sputum is regarded as a reliable one.

Pulmonary or oropharynx *C. laurentii* infection is rare and has been recorded only in immunity defense-impaired patients [3]. Only a previous *C. laurentii* lung infection has been reported in a subject with unknown underlying disease and two cases of *C. laurentii* presence in cadavers belonging to non-immunosuppressed subjects, where there was also a co-infection with *C. neoformans* strains. Our patient presented pulmonary *C. laurentii* infection which is the first reported in a living non-immunocompromised subject.

Additionally, this is the first case of simultaneous pulmonary infection of *C. laurentii* and *M. tuberculosis* in otherwise healthy or non-immunosuppressed subjects. Concomitant cerebral tuberculosis and cryptococcosis are extremely rare in the literature, affecting only HIV patients [3].

There is no standard treatment for *C. laurentii* infection. In a number of series, *C. laurentii* has been successfully treated with amphotericin B (94%) or fluconazole [8]. In vitro evidence about the susceptibility of *C. laurentii* to antifungal agents, suggests that *C. laurentii* strains are mainly sensitive to amphotericin B and itraconazole. Itraconazole, ketoconazole and voriconazole are scarcely preferred, though itraconazole has better tissue bioavailability in lungs compared to fluconazole. Fluconazole is strongly indicated for fungemia due to *C. laurentii*. Drug susceptibility testing should be conducted before any commencement of

treatment. Antifungal resistance is associated with melanin deposition of the strains [12] and is referred mainly for fluconazole and flucytosine. It has been also related to prior azole administration and other host comorbidities [1]. Nevertheless, in a previous study testing drug susceptibility of yeasts found in synanthropic bird faecal samples, *C. laurentii* was found highly resistant in 11 antimycotic agents [10]. *C. laurentii* found in our patient was also highly resistant to all common antifungals (fluconazole, amphotericin B, itraconazole, voriconazole). Importantly, this evidence highlights that these rare infections can be severe and even fatal, due to our inability to efficiently combat with these highly resistant *C. laurentii* strains. Apart from resistance to antifungal agents, advanced age and CNS involvement have been identified as poor prognostic factors [1].

The current report describes the first case of *C. laurentii* concomitant lung infection with *M. tuberculosis* in a non-immunocompromised patient. *C. laurentii* has recently been recognized as an opportunistic fungal pathogen in immunosuppressed subjects but remains extremely rare in healthy subjects. Early suspicion and diagnosis are critical to prompt treatment. It is critical to remain vigilant for Cryptococcosis lung infections even in non-immunosuppressed patients as they may be lethal and mimic other lung diseases.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Khawcharoenporn, T, Apisarnthanarak, A, Mundy, LM. Non-neoformans cryptococcal infections: a systematic review. *Infection*, **2007**; 35:51-8.
2. Roberts, GD, Washington, JA, Detection of fungi in blood cultures. *J Clin Microbiol*, **1975**; 1:309-10.
3. Shankar, EM, Kumarasamy, N, Bella, D et al. Pneumonia and pleural effusion due to *Cryptococcus laurentii* in a clinically proven case of AIDS. *Can Respir J*, **2006**; 13:275-8.

4. Pedroso, RS, Ferreira, JC, Candido, RC. The isolation and characterization of virulence factors of *Cryptococcus* spp. from saprophytic sources in the city of Ribeirao Preto, Sao Paulo, Brazil. *Microbiol Res*, **2009**; 164:221-7.
5. Bauters, TG, Swinne, D, Boekhout, T, Noens, L, Nelis, HJ. Repeated isolation of *Cryptococcus laurentii* from the oropharynx of an immunocompromised patient. *Mycopathologia*, **2002**; 153:133-5.
6. McCurdy, LH, Morrow, JD. Infections due to non-neoformans cryptococcal species. *Compr Ther*, **2003**; 29:95-101.
7. Krcmery, V, Jr., Kunova, A, Mardiak, J. Nosocomial *Cryptococcus laurentii* fungemia in a bone marrow transplant patient after prophylaxis with ketoconazole successfully treated with oral fluconazole. *Infection*, **1997**; 25:130.
8. Lynch, JP, 3rd, Schaberg, DR, Kissner, DG, Kauffman, CA. *Cryptococcus laurentii* lung abscess. *Am Rev Respir Dis*, **1981**; 123:135-8.
9. Sinnott, JT, Rodnite, J, Emmanuel, PJ, Campos, A. *Cryptococcus laurentii* infection complicating peritoneal dialysis. *Pediatr Infect Dis J*, **1989**; 8:803-5.
10. Lord, AT, Mohandas, K, Somanath, S, Ambu, S. Multidrug resistant yeasts in synanthropic wild birds. *Ann Clin Microbiol Antimicrob*; 9:11.
11. Furman-Kuklinska, K, Naumnik, B, Mysliwiec, M. Fungaemia due to *Cryptococcus laurentii* as a complication of immunosuppressive therapy-a case report. *Adv Med Sci*, **2009**; 54:116-9.
12. Ikeda, R, Sugita, T, Jacobson, ES, Shinoda, T. Laccase and melanization in clinically important *Cryptococcus* species other than *Cryptococcus neoformans*. *J Clin Microbiol*, **2002**; 40:1214-8.

Figures and Figures Legends



Figure 1 A : Posteroanterior chest radiograph shows left upper lobe consolidation and a cavitary opacity in the left upper lobe, **B.** Chest CT revealing caseous necrosis and ground glass opacities in the left upper lobe, **C.** Chest CT revealing a cavity with irregular borders and air-fluid levels, secondary to caseous necrosis, surrounded by thick outer wall




Figure 2 : The Gram's stain revealed spherical and elongated budding yeast-like cells without any pseudohyphae, identified as *C .laurentii*. India ink was also used for early visualization of the capsule that gave the characteristic "halo" around the cell (not shown here)



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY
Volume 14 Issue 2 Version 1.0 Year 2014
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Hyper-Immunoglobulin E Syndrome in a Neonate: A Case Report

By İlyas Yolbas, Velat Sen, Bilal Sula, Lokman Timuragaoglu & Hasan Balik

Dicle University, Medical School, Diyarbakir, Turkey

Abstract- Hyper-immunoglobulin E syndrome (Job syndrome) is a rare primary immunodeficiency with variable presentation, characterized by recurrent infections, facial dimorphism, eczema, scoliosis, joint hyper-extensibility, pathologic fractures, very high IgE (>2000 IU/mL), severe eosinophilia and variable impaired T cell function. We present a case of Hyperimmunoglobulin E syndrome in neonate with review of the literature. *J Microbiol Infect Dis* 2013; 3(3): 144-146.

Keywords: *hyper-immunoglobulin E syndrome, recurrent infections, neonate.*

GJMR-C Classification : *NLMC Code: WF 250*



Strictly as per the compliance and regulations of:



© 2014. İlyas Yolbas, Velat Sen, Bilal Sula, Lokman Timuragaoglu & Hasan Balik. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License <http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hyper-Immunoglobulin E Syndrome in a Neonate: A Case Report

Bir yenidoğanda Hiperimmunglobulin E sendromu: Olgu sunumu

Ilyas Yolbaş^α, Velat Şen^σ, Bilal Sula^ρ, Lokman Timurağaoğlu^ω & Hasan Balık[¥]

Abstract- Hyper-immunoglobulin E syndrome (Job syndrome) is a rare primary immunodeficiency with variable presentation, characterized by recurrent infections, facial dimorphism, eczema, scoliosis, joint hyper-extensibility, pathologic fractures, very high IgE (>2000 IU/mL), severe eosinophilia and variable impaired T cell function. We present a case of Hyperimmunoglobulin E syndrome in neonate with review of the literature. *J Microbiol Infect Dis* 2013; 3(3): 144-146.

Keywords: hyper-immunoglobulin E syndrome, recurrent infections, neonate.

Özet- Hiper-immunglobulin E sendromu (Job Sendromu), genellikle çok yüksek IgE (> 2000 IU/ml) seviyesi, şiddetli eozinofili, soğuk stafilokok cilt absesi ve pnömoni gibi tekrarlayan enfeksiyonlar, egzama, skolyoz, eklem hiperextansibilitesi, patolojik kırıklar, tipik bir yüz görünümü, kraniyosinostoz ve değişken bozulmuş T hücre fonksiyonu ile karakterize nadir görülen primer κ ubclass yetmezlik durumudur. Hiper-immunglobulin E sendromu yenidoğan ve diğer yaş grubunda farklı laboratuvar bulguları, klinik belirti ve bulguları gösterebilir. Bu çalışmada soğuk Stafilokokal cilt abseleri, hafif yüksek total serum IgE düzeyi (146 IU/ml, normal: 0-8 IU/ml), yüksek κ ubclass eozinofili (% 15) ve normal serum IgA, IgG, IgG κ ubclass, IgM, C3 ve C4 seviyelerine sahip hiper-immunglobulin E sendromu olan onbeş günlük erkek hasta sunuldu.

Anahtar Kelimeler: hiper-immunglobulin E sendromu, job sendromu, yenidoğan.

I. INTRODUCTION

Hyper-immunoglobulin (Ig) E syndrome (HIES or Job Syndrome) is a rare primary immunodeficiency generally characterized by recurrent infections such as staphylococcal cold skin abscesses and pneumonia, eczema, scoliosis, joint hyperextensibility, pathologic fractures, a typical facial appearance, craniosynostosis, very high IgE, severe eosinophilia, and variable impaired T cell functions. The mechanisms responsible for hyperproduction of IgE and eosinophils in patients with HIES are presently unknown. Generally the onset of HIES occurs in children and elderly individuals.^{1,2} HIES may have variable presentation, and laboratory values in different age groups.^{3,4}

Author α σ ω : Department of Pediatrics, Dicle University, Medical School, Diyarbakir, Turkey. e-mail: ilyasyolbas@hotmail.com

Author ρ : Department of Dermatology, Dicle University, Medical School, Diyarbakir, Turkey.

Author $\¥$: Diyarbakir Children's Hospital, Diyarbakir, Turkey.

We present a 15-days old newborn with HIES whose only have staphylococcal cold skin abscesses eosinophilia and high immunoglobulin E levels.

II. CASE REPORT

A fifteen-days-old male neonate born at 40 weeks of gestation by normal spontaneous vaginal birth to a 24 years-old mother without history of significant disease such as eczema or HIES in the family. The antenatal ultrasonography was normal. The patient was admitted to Dicle University Hospital at fifteenth day of his life, because of cold abscess that appeared 5 days before admission. On physical examination there was a 2x3 cm swelling compatible with cold abscesses in the anterior right knee area, right supraclavicular area, lateral right chest area and anterior left ankle area. He also had a characteristic facial appearance such a broad nasal bridge, cheilitis, thickened skin, and deep-set eyes with a prominent chin and forehead (Figure 1-3). There were no eczematous rash, scoliosis, fractures history, joint hyperextensibility and craniosynostosis on his physical examination and history. Yolbaş İ, et al. Hyper-immunglobulin E syndrome 145 *J Microbiol Infect Dis* www.jmidonline.org Vol 3, No 3, September 2013 The patient had slightly higher total serum IgE level (146 IU/mL, normal range: 0-8 IU/mL), high peripheral eosinophilia (15%) and normal serum IgA, IgG, IgG subclasses, IgM, C3 and C4 levels. The patient's other biochemical parameters were normal. The neonate underwent incision with pus aspirated which later grew *Staphylococcus aureus*. The skin biopsy showed eosinophil infiltration. Staphylococcal cold skin abscesses were treated with Ampicillin-sulbactam after drainage. HIES was diagnosed by clinically and laboratory tests, because there are no genetic or other confirmatory tests available in Turkey. The patient's computed tomography of the lungs was normal. The patient's Dual-energy X-ray absorptiometry test was found normal. The patient was discharged after two week from the hospital without any complications.

III. DISCUSSION

HIES is a multi-system disorder with a wide range of clinical phenotypes and signs, including skeletal, connective tissue, and vascular abnormalities.³ Most of patients with HIES suffer from recurrent staphylococcal infections of skin and lungs.⁴ Generally recurrent pyogenic pneumonias start in early childhood, and the most common infecting organisms are Staphylococcal aureus, Haemophilus influenzae and Streptococcus pneumoniae. Also mucocutaneous candidiasis is common in HIES.⁴ Musculoskeletal abnormalities of HIES are scoliosis, osteopenia, minimal trauma fractures, hyperextensibility and degenerative joint disease.^{3,5} The patients with HIES may have problem with development of their teeth.⁶ Our case had multiple cold skin abscesses in the various regions of body but had no other stigmata of HIES at this age. Characteristic facial appearance of HIES include broad nasal bridge, cheilitis, thickened skin, and deep-set eyes with a prominent chin and forehead.³ Our case had the similar characteristic facial appearance such as broad nasal bridge, cheilitis, thickened skin, and deep-set eyes with a prominent chin and forehead.

The two most consistent laboratory abnormalities in HIES are eosinophilia and elevated serum IgE. Over time, the serum IgE may decline in adults or may increase in newborn.³ Demirci et al⁷ found that IgE level of a two-month-old patient with HIES was 75.3 IU/ml (Range: 15-32 IU/ml), But in the same patients' they found IgE level 13,000 IU/ml after eight months. The patients with HIES have normal serum IgM, IgG, and IgA levels.³ Our case have had slightly higher total serum IgE level as 146 IU/ 146 Yolbaş İ, et al. Hyper-immunglobulin E syndrome J Microbiol Infect Dis www.jmidonline.org Vol 3, No 3, September 2013 mL (Normal range: 0-8 IU/mL) and high peripheral eosinophilia (15%).

The diagnosis of HIES is usually made based on characteristic facial appearance and clinical features associated with high serum IgE level and eosinophilia.⁵ Our patient had some of the characteristic features and laboratory findings. However definitive diagnosis is made on genetic basis such as STAT3.

Management of HIES currently revolve around prevention and treatment of infections. There is no cure for HIES at present. Therapy includes drainage of cutaneous abscesses followed by intravenous antibiotic therapy directed against mostly staphylococcal aureus. Prophylactic antibiotics and specific treatment is based on organ involvement. Immunoglobulin replacement therapy and some other treatments such as IFN-g, IFN-a, histamine-2 antagonists, and cyclosporine have been tried, which seem to be useful in the management of patients with HIES.^{2,8} Prophylactic antibiotic or antifungal prophylaxis (e.g., trimethoprim-sulfamethoxazole or fluconazole) should be recommended in the patients



Figure 1 : Characteristic facial appearance such a broad nasal bridge, cheilitis, thickened skin, and deep-set eyes with a prominent chin and forehead, and Staphylococcal cold skin abscesses on right supraclavicular area



Figure 2 : Staphylococcal cold skin abscesses on lateral right chest area



Figure 3 : Staphylococcal cold skin abscesses on anterior

with HIES with recurrent sinopulmonary, cutaneous infections, mucocutaneous candidiasis and invasive fungal infections.⁸

In conclusion, HIES may present with some features in the newborn baby. Recognition of leading signs of the disease will provide early diagnosis and prophylactic measures.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Shemer A, Weiss G, Confino Y, Trau H. The hyper-IgE syndrome. Two cases and review of the literature. *Int J Dermatol* 2001;40:622-628.
2. Schimke LF, Sawalle-Belohradsky J, Roesler J, et al. Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. *J Allergy Clin Immunol* 2010;126:611- 617.
3. Olaiwan A, Chandesris MO, Fraitag S, et al. Cutaneous findings in sporadic and familial autosomal dominant hyper-IgE syndrome: a retrospective, single-center study of 21 patients diagnosed using molecular analysis. *J Am Acad Dermatol* 2011;65:1167-1172.
4. Minegishi Y, Karasuyama H. Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. *Int Immunol* 2009;21:105-112.
5. Woellner C, Gertz EM, Schøffer AA, et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. *J Allergy Clin Immunol* 2010;125:424-432.
6. Eberting CL, Davis J, Puck JM, et al. Dermatitis and the newborn rash of hyper-IgE syndrome. *Arch Dermatol* 2004;140:1119-1125.
7. Demirel N, Bas AY, Zenciroglu A. Can necrotizing fasciitis be the first symptom of Hyperimmunoglobulin E syndrome? *Indian J Pediatr* 2008;75:1090.
8. Yeganeh M, Gambineri E, Abolmaali K, et al. Other well-defined immunodeficiencies. Primary immunodeficiency diseases: definition, diagnosis and management. In: Rezaei N, Aghamohammadi A, Notarangelo LD, editors. Berlin: Springer; 2008;251-290.





This page is intentionally left blank



GLOBAL JOURNAL OF MEDICAL RESEARCH: C
MICROBIOLOGY AND PATHOLOGY
Volume 14 Issue 2 Version 1.0 Year 2014
Type: Double Blind Peer Reviewed International Research Journal
Publisher: Global Journals Inc. (USA)
Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Staphylococcus aureus and its Antimicrobial Susceptibility Pattern in Patients, Nasal carriage of Health Personnel, and objects at Dessie referral hospital, Northern Ethiopia

By Zerfie Tadesse, Moges Tiruneh & Mucheye Gizachew
University of Gondar, Ethiopia

Abstract- Introduction: *Staphylococcus aureus* is one of the most common causes of healthcare and community associated infections. Its remarkable ability to acquire antimicrobial resistance mechanisms and advantageous pathogenic determinants has contributed to emergence of infections in both nosocomial and community settings.

Objective: To determine prevalence of *Staphylococcus aureus* and antibacterial susceptibility patterns in patients, nasal carriage of health personnel and objects of Dessie Referral Hospital.

Methods: Cross sectional study was conducted at Dessie Referral Hospital from February 01 to May 30, 2013. Using a convenient sampling technique, 180 specimens of pus, blood, nasal swab and swab from hospital objects were collected and cultured by standard procedure. Growth identification was based on colony morphology, Gram staining and results of biochemical tests. Antibacterial susceptibility testing was done by disk diffusion method on Mueller-Hinton agar.

Keywords: *Staphylococcus aureus, antimicrobial susceptibility, ethiopia.*

GJMR-C Classification : NLMC Code: QW 161.5.S8



Strictly as per the compliance and regulations of:



Staphylococcus aureus and its Antimicrobial Susceptibility Pattern in Patients, Nasal carriage of Health Personnel, and objects at Dessie referral hospital, Northern Ethiopia

Zerfie Taddesse ^α, Moges Tiruneh ^σ & Mucheye Gizachew ^ρ

Abstract- Introduction: *Staphylococcus aureus* is one of the most common causes of healthcare and community-associated infections. Its remarkable ability to acquire antimicrobial resistance mechanisms and advantageous pathogenic determinants has contributed to emergence of infections in both nosocomial and community settings.

Objective: To determine prevalence of *Staphylococcus aureus* and antibacterial susceptibility patterns in patients, nasal carriage of health personnel and objects of Dessie Referral Hospital.

Methods: Cross sectional study was conducted at Dessie Referral Hospital from February 01 to May 30, 2013. Using a convenient sampling technique, 180 specimens of pus, blood, nasal swab and swab from hospital objects were collected and cultured by standard procedure. Growth identification was based on colony morphology, Gram staining and results of biochemical tests. Antibacterial susceptibility testing was done by disk diffusion method on Mueller-Hinton agar.

Result: Overall prevalence of *Staphylococcus aureus* was 40.5% and its occurrence in inpatients, health personnel and objects was 57.5%, 40% and 34.3% respectively. Penicillin G (90.4%), nalidixic acid (93.2%), and amoxicillin (82.9%) showed high level of resistance, whereas, gentamicin (84.3%), tetracycline (62.9%) chloramphenicol (63.6%), ciprofloxacin (61.6%), and kanamycin (64.4%) were relatively effective against *Staphylococcus aureus* infection. Vancomycin exhibited 100% susceptible in all study subjects.

Conclusion: *Staphylococcus aureus* is still the most common cause of nosocomial infection and multi-resistant was very high and most of the isolates showed high levels of resistance to commonly used antimicrobials. In the absence of diagnostic bacteriologic services, vancomycin and gentamicin are the best therapeutic options to treat *S. aureus* infections.

Keywords: *Staphylococcus aureus*, antimicrobial susceptibility, Ethiopia.

I. BACKGROUND

S *Staphylococcus aureus* (*S. aureus*) belongs to the genus *Staphylococcus*, which has more than 20 species. *S. aureus* is a Gram-positive coccus,

catalase and coagulase positive and causes diseases through the production of toxins and enzymes and through direct invasion and destruction of tissues (1). It is one of the most common causes of healthcare- and community-acquired infections, such as localized cutaneous and life threatening systemic infections. Although most community infections are treated in the outpatient setting, some invasive infections, including bacteremia, septic arthritis, toxic shock syndrome, osteomyelitis, and endocarditis, have devastating complications and may require hospitalization (2, 3). Hospitalized patients are unusually at high risk of infection for various reasons, and tend to be more susceptible to infections. *S. aureus* causes more severe diseases in immunocompromised patients than in immune competent ones (4).

S. aureus is one of the most successful and adaptable human pathogens. Its remarkable ability to acquire antibiotic-resistance mechanisms and advantageous pathogenic determinants has contributed to emergence of infections in both nosocomial and community settings. However, because of different selective pressures, several notable differences exist between nosocomial-and community-acquired strains (5). Healthcare workers are potential source of hospital-acquired infections. Pathogens are transmitted by carriage on hands from inanimate objects present in the hospital setting (6). However, the role of fomites and the inanimate hospital environment (e.g. surfaces and medical equipment) in the transmission of healthcare associated infections is controversial (7). Nasal carriage of *S. aureus* plays a key role in the development of *S. aureus* infections. It is a major risk for the development of infection in patients undergoing hemodialysis, continuous ambulatory peritoneal dialysis, surgical patients, and patients with intravascular devices (8).

Multidrug-resistant strains of *S. aureus*, particularly methicillin resistant *S. aureus* (MRSA), pose a major clinical and epidemiological problem in hospitals, as they are easily transferred among hospital staff and patients (9). Antimicrobial resistance among nosocomial pathogens is a significant problem in many countries with severe consequences including increased medical

Author ^α: Department of Bacteriology, Dessie Regional Research Laboratory, Dessie, Northeast Ethiopia.

Author ^σ ^ρ: Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, University of Gondar.

e-mail: muchegiza@gmail.com

costs, morbidity and mortality of patients (10). Since the first isolation of MRSA in the United Kingdom in 1961 (11), increasing rates of methicillin resistance among *S. aureus* strains have been a cause for concern, especially in developed countries. Until recently, vancomycin was believed to have retained activity against all strains of MRSA; therefore, the spread of MRSA has led to increased vancomycin usage and hence increased selective pressure for the development of resistance (12). The first report of MRSA in Ethiopia was made from 1987-1988 and the overall MRSA isolation rate was 31% while 71% out of the MRSA strains were multiple drug resistant (13). Nosocomial infection causes substantial morbidity and mortality, prolong hospital stay of patients, and increase direct patient-care costs. Widespread uses of antibiotics, together with length of time over which they have been available have led to major problems of resistant organisms. *S. aureus* as a cause of various nosocomial infections has not been recognized in Dessie Referral Hospital. Studying staphylococcal nosocomial infections in the area is essential for early prevention and control, correct diagnosis and treatment, and reducing morbidity and mortality of hospitalized patients owing to this infection. The aim of this study was therefore to assess prevalence of *S. aureus* and its susceptibility pattern to antimicrobials in inpatients isolates, nasal carriage of hospital personnel and hospital objects of Dessie Referral Hospital.

II. MATERIAL AND METHOD

a) Study area

The study was conducted in Dessie, capital of South Wollo Zone in Amhara Regional State Northern Ethiopia, located 401 km far from Addis Ababa, on the way to Asmara. This town has a latitude and longitude of 11°8'N 39°38'E/11.133°N 39.633°E with an elevation of between 2,470 and 2,550 meter above sea level. The town has an estimated total population of 151,094 of whom, 78,203 are women (14). Dessie has one referral hospital, three general hospitals (private), three health centers, five higher clinics (private) and one regional health research laboratory where culture and susceptibility tests are performed.

b) Study Design and period

A cross sectional study was conducted from February 01 to May 30, 2013.

III. POPULATION

a) Source population

All patients visited Dessie referral hospital, all health personnel who were working in this hospital and Objects (blankets, floor and cupboards) which were being used by patients in the hospital.

b) Study population

All patients who were admitted to Dessie referral hospital and who had developed signs and symptoms of hospital acquired infection after 48hrs of admission during the study period, all health personnel who were working in inpatient wards of the hospital and who were willing to participate in the study and the objects (blankets, cupboards and floor) which were being used by patients in the hospital.

c) Inclusion criteria

Patients who had signs and symptoms of hospital acquired infection after 48 hours of admission to hospital, and health personnel who had not antimicrobials within seven days of specimen collection during the study period.

IV. VARIABLES

a) Dependent variable

Prevalence and antimicrobial susceptibility pattern of *S. aureus*

b) Independent variables

Sex, age, hospitalization, catheterization, surgery

c) Sample size determination and sampling technique

Convenient sampling technique was used. All the 40 patients who had developed signs and symptoms of hospital acquire infection during the study period were included in the study. Thirty five volunteer health personnel in five inpatient wards (medical, surgical, gynecology, pediatric and orthopedic) were also included. In addition, 105 specimens were taken from Objects (blanket, cupboards and floor) that could be touched with hands of health personnel and patients within the five wards.

V. DATA COLLECTION AND LABORATORY METHODS

a) Socio-demographic data collection

Data on socio-demographic characteristics from each study participant was collected using pre-tested questionnaire guided interview.

b) Specimen collection

Specimens were collected from the study participants using the standard operational procedures. Thirty six swabs of wound secretions were aseptically obtained from patients after patients were diagnosed as wound sepsis by a physician. The specimens were collected with sterile cotton swabs before the wound was cleaned with an antiseptic solution and 10ml of four blood samples were aseptically collected from each patient, and mixed into blood culture bottle containing 90ml of nutrient broth. Nasal swabs were taken from 35 health personnel with sterile cotton swab. A separate sterile cotton swab was passed into the anterior nares of both the nostrils and rotated in both directions and then

placed into sterile test tube. One hundred five specimens were collected from Objects (blanket, cupboards and floor). Sterile cotton swabs moistened with normal saline was rotated against the surface of objects to obtain specimens. All collected specimens were labeled and transported to Dessie Regional Health Research Laboratory for culturing and antimicrobial susceptibility testing.

c) Bacterial isolation and identification

Swab specimens were cultured onto mannitol salt agar and incubated at 35-37°C for 24 hrs. Each culture was read and then sub-cultured onto blood agar and incubated at 35-37°C for 24 hrs. Blood samples were incubated at 35-37°C for 7-14 days (until growth was seen) and growth was sub-cultured on mannitol salt agar. Identification of growth was based on colony morphology, Gram staining and appropriate biochemical test. *S. aureus* is a gram positive, beta hemolytic, catalase, and coagulase positive.

d) Antimicrobial susceptibility testing

Antimicrobial susceptibility testing of isolates was performed using disk diffusion method on Muller-Hinton agar plates as per the National Committee for Clinical Laboratory standards (15). Single colony was selected and emulsified in 3ml sterile normal saline solution in a sterile test tube. The turbidity of the suspension was then adjusted to the density of a barium chloride standard (0.5 McFarland) in order to standardize the size of inoculums. A sterile cotton swab was dipped into the standardized suspension of the bacterial culture, squeezed against the sides of the test tube to remove the excess fluid and inoculated onto Mueller-Hinton agar and allowed to dry the flood. Thereafter, antimicrobial discs were placed on the agar with forceps and gently pressed down to ensure contact. The plates were then allowed to stand for 30 minutes for diffusion of active substance of the agents. Plates were inverted and incubated at 35-37°C for 24 hrs. An inhibition zone diameter of each antimicrobial was then measured and interpreted as 'Resistant', 'Intermediate' and 'Sensitive' by comparing with recorded diameters of a control organism, ATCC25923 (16). Antimicrobials used, include oxacillin (1µg), vancomycin (30 µg), penicillin G (10IU), tetracycline (30µg), sulphamethoxazole (25 µg), chloramphenicol (30µg), gentamicin (10µg), ciprofloxacin (5µg), nalidixic acid (30µg), amoxicillin (10µg), ceftriaxone (30µg) and

kanamycin (30 µg). All media and antibiotics used were Oxoid, UK products.

e) Quality control

Pre-tested questionnaire guided interview was used for data collection on socio-demographic characteristics. Specimens were collected and processed according to the standard operating procedure. Sterility of culture media was checked by incubating 5% of the batch at 35-37°C overnight and observed for bacterial growth and the standard reference strains, *S aureus* ATCC25923 (16) was tested weekly as controls on the biochemical tests and agar plates including Mueller Hinton agar with antimicrobial discs to assure testing performance of the potency of antimicrobial discs.

f) Data processing and analysis

Data was checked for its completeness and entered and analyzed using SPSS statistical software version 16.0. Results were explained in words and tables. Proportions for categorical variables were compared using chi-square test. In all cases P-value less than 0.05 was taken as statistically significant.

g) Ethical consideration

The project was started after ethical clearance was obtained from the Ethical Clearance Committee of School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar. Written informed consent was obtained from the study participants. Permission was obtained from Dessie Referral Hospital. For each confirmed infection cases, the responsible clinician of the participant was informed and treatment was started as per the culture result and antimicrobial susceptibility pattern. Confidentiality of information of the participants was maintained.

VI. RESULTS

a) Prevalence of S. aureus infection in inpatients, nasal carriage of health personnel and hospital objects

Of 180 specimens collected, 40(22.2%) were from inpatients, 35(19.4%) from health personnel and 105(58.3%) from hospital objects. From 40 inpatients, 36(90%) had undergone surgery and developed hospital acquired wound infections and the other 4 (10%) were blood samples. A total of 73 *S. aureus* isolates were identified and of which, 23(31.5%), 14(19.2%), and 36(49.3%) were from inpatients, health personnel and objects respectively(table1)..

Table 1 : Prevalence of *S. aureus* infection in inpatients, health personnel and objects at Dessie Referral Hospital, May 2013

Study participants	<i>S. aureus</i> status		
	Positive (%)	Negative (%)	Total (%)
Inpatients	23(57.5)	17(42.5)	40(22.2)
Health personnel	14 (40)	21 (60)	35 (19.4)
Hospital objects	36 (34.3)	69 (65.7)	105(58.3)
Total	73 (40.5)	107 (59.5)	180 (100)

As it is shown in table2, among 36 *S. aureus* isolates of objects, 13 were from blankets, 10 from cupboards and 13 from floor. Based on this finding, there was no significant difference (p=0.684) among these objects on the prevalence of *S. aureus*.

Table 2 : *S. aureus* isolates from objects* at Dessie Referral Hospital, May 2013

Variable	<i>S. aureus</i> status			P-value
	Positive	Negative	Total	
Hospital objects				0.684
Blankets	13 (36%)	22 (64%)	35 (33.3%)	
Cupboards	10 (27.7%)	25 (72.3%)	35 (33.3)	
Floor	13 (36%)	22 (64%)	35 (33.3%)	
Total	36 (34.3%)	69 (65.7%)	105 (100%)	

*blankets, cupboards and floor

b) *S. aureus* infection in relation to sex and age groups of inpatients and health personnel

As presented in table 3, a total of 75: inpatients (40) and health personnel (35) had participated in the

study. Of these, 45(60%) were females. Among 40 inpatients, 22 were females. From males, 61.1% and from females, 54.5% had *S. aureus* infection. Among 35 health personnel, 23 were females.

Table 3 : *S. aureus* infection in relation to sex and age groups of inpatients and health personnel at Dessie Referral Hospital, May 2013

Sex	Inpatients			Health personnel		
	Positive (%)	Negative (%)	Total (%)	Positive (%)	Negative (%)	Total (%)
Male	11 (61.1)	7 (38.9)	18 (45)	2 (16.7)	10 (28.6)	12 (34.3)
Female	12 (54.5)	10(45.5)	22 (55)	12(83.3)	11 (31.4)	23(65.7)
Total	23(57.5)	17(42.5)	40(100)	14 (40)	21(60)	35 (100)
Agegroup (year)						
0-10	0 (0)	2 (100)	2 (5)	0 (0)	0 (0)	0 (0)
11-20	2 (66.7)	1 (33.3)	3 (7.5)	0 (0)	0 (0)	0 (0)
21-30	10 (60)	7 (40)	17 (42.5)	5 (31.2)	11 (68.8)	16 (45.7)
31-40	4 (50)	4 (50)	8 (22.9)	4 (57.1)	3 (53.9)	7 (20)
≥41	7 (75)	3 (25)	10 (28.6)	5 (41.7)	7 (58.3)	12 (34.3)

c) Antimicrobial susceptibility pattern of *S. aureus* infection

Antimicrobial resistance patterns of *S. aureus* infection was 43.8%, 0%, 90.4%, 38.4%, 45.2%, 34.2%, 6.8%, 37%, 93.2%, 83.6%, 47.9%, and 35.6% for oxacillin, vancomycin, penicillin G, tetracycline, sulphamethoxazole, chloramphenicol, gentamicin, ciprofloxacin, nalidixic acid, amoxicillin, ceftriaxone,

and kanamycin respectively. High level of resistance was demonstrated to penicillin G (90.4%), nalidixic acid (93.2%), and amoxicillin (82.9%), whereas, gentamicin (84.3%), tetracycline (62.9%) chloramphenicol (63.6%), ciprofloxacin (61.6%), and kanamycin (64.4%) were relatively sensitive to *S. aureus* infection. Vancomycin exhibited 100% susceptible in all study participants (table4).

Table 4 : Antimicrobial susceptibility patterns of all *S. aureus* isolates (n=73) from inpatients, health personnel and objects at Dessie Referral Hospital, May 2013

Antimicrobial agents	Antimicrobial susceptibility patterns			
	Susceptible	Resistance	Intermediate	Total
Oxacillin	41(56.2%)	32 (43.8%)	0(0%)	73(100%)
Vancomycin	73(100%)	0 (0%)	0(0%)	73(100%)
penicillin G	6(8.6%)	66 (90%)	1(1.4%)	73(100%)
Tetracycline	45(62.9%)	28(37.1%)	0(0%)	73(100%)
Sulphamethoxazole	35(47.1%)	33(45.7%)	5(7.1%)	73(100%)
Chloramphenicol	47(62.9%)	25(35.7%)	1(1.4%)	73(100%)
Gentamicin	62(84.3%)	5(7.1%)	6(8.6%)	73(100%)
Ciprofloxacin	45(62.9%)	27(35.7%)	1(1.4%)	73(100%)
Nalidixic acid	1(1.4%)	68(92.9%)	4(5.7%)	73(100%)
Amoxicillin	10(14.3%)	61(82.9%)	2(2.9%)	73(100%)
Ceftriaxone	34(48.6%)	35(47.1%)	4(4.3%)	73(100%)
kanamycin	47(62.9%)	26(37.9%)	0(0%)	73(100%)

Different antimicrobials showed different antimicrobial susceptibility patterns in different study participants. Resistance pattern of isolates for nalidixic acid (91.3%), penicillin G(100%) and amoxicillin (100 %) were demonstrated in inpatient, whereas, in health

personnel, the level of resistance were 85.7% for nalidixic acid, 92.9% penicillin G and 78.6% amoxicillin. In objects, the level of resistance for nalidixic acid, penicillin G and amoxicillin were 97.2% 83.3% and 75% respectively (table5).

Table 5 : Antimicrobial susceptibility patterns of *S. aureus* isolates from inpatients, health personnel and objects at Dessie Referral Hospital, May 2013

Antimicrobial agents	Study participants and antimicrobial susceptibility patterns								
	Inpatients			Health personnel			Objects		
	S (%)	R (%)	I (%)	S (%)	R (%)	I (%)	S (%)	R (%)	I (%)
Oxacillin	14(60.9)	9(39.1)	0(0)	11(78.6)	3(21.4)	0(0)	16(44.4)	20(55.6)	0(0)
Vancomycin	23(100)	0(0)	0(0)	14(100)	0(0)	0(0)	36(100)	0(0)	0(0)
penicillin G	0(0)	23(100)	0(0)	1(7.1)	13(92.9)	0(0)	5(13.9)	30(83.3)	1(1.4)
Tetracycline	16(69.6)	7(30.4)	0(0)	7(50)	7(50)	0(0)	22(61.1)	14(38.9)	0(0)
Sulphamethoxazole	12(52.2)	9(39.1)	2(8.7)	8(57.1)	5(35.7)	1(7.1)	15(41.7)	19(52)	2(5.6)
Chloramphenicol	16(69.6)	6(26.1)	1(4.3)	12(85.7)	2(14.3)	0(0)	19(52.8)	17(47.2)	0(0)
Gentamicin	22(95.7)	0(0)	1(4.3)	14(100)	0(0)	0(0)	26(72.2)	5(13.9)	5(13.9)
Ciprofloxacin	15(65.2)	8(34.8)	0(0)	10(71)	3(21.4)	1(7.1)	20(55.5)	16(44.5)	0(0)
Nalidixic acid	0(0)	21(91.3)	2(8.7)	0(0)	12(85.7)	2(14.3)	1(2.8)	35(97.2)	0(0)
Amoxicillin	0(0)	23(100)	0(0)	2(14.3)	11(78.6)	1(7.1)	8(22.2)	27(75)	1(2.8)
Ceftriaxone	10(43.5)	10(43.5)	3(13)	10(71.4)	3(21.4)	1(7.1)	14(38.9)	22(61.1)	0(0)
kanamycin	18(78.3)	5(21.7)	0(0)	10(71.4)	4(28.6)	0(0)	19(52.8)	17(47.2)	0(0)

S= susceptible R= resistance I= intermediate

d) Multi drug resistance pattern of *S. aureus* isolates from inpatients, health personnel and objects

Multi-drug resistance (resistance to ≥2 drugs) was recorded in 79 (95.9 %) of *S. aureus* isolates. About half, 39(53.4%) of the isolates were demonstrated resistant to at least five antibacterials. Four (5.5%), 2

(2.7%), 17 (23.3%) and 11(15.1%) of the *S. aureus* were found to be resistant for one, two, three and four antibacterials respectively. None of the *S. aureus* isolates were susceptible for all tested antibacterials (table6).

Table 6 : Multi drug resistance pattern of *S. aureus* isolates from inpatients, health personnel and objects, at DRH*, May 2013

Study participants	Antibiogram pattern						Total
	R0	R1	R2	R3	R4	≥R5	
Patients	0(0%)	0(0%)	1(4.3%)	5(21.7%)	4(17.4%)	13(56.5%)	23(31.5%)
Health personnel	0(0%)	0(0%)	1(7.1)	5(35.7%)	3(21.4%)	5(35.7%)	14(19.2%)
Objects	0(0%)	4(11.1%)	0(0%)	7(19.4%)	4(11.1%)	21(58.3%)	36(49.3%)
Total	0(0%)	4(5.5%)	2(2.7%)	17(23.3%)	11(15.1%)	39(53.4%)	73(100%)

R0= resistant to zero antimicrobial
R1= resistant to one antimicrobial
R2= resistant to two antimicrobial

R3= resistant to three antimicrobial
R4= resistant to four antimicrobial
R≥5= resistant to greater or equals to five antimicrobial

*Dessie referral hospital

VII. DISCUSSION

Results of previous studies which are also confirmed in this study had shown that *S. aureus* is the common cause of nosocomial infection. Overall prevalence of *S. aureus* infection in this study (table1) is comparable to other study done elsewhere in the world (37.3%) (17). The present study also showed that the frequency of *S. aureus* isolated from hospital objects of different wards (table2) is consistent with studies done in Gondar and Nigeria (17,18).

One of the important sources of *S. aureus* for nosocomial infection is nasal carriage among hospital personnel (19). In this study, prevalence of *S. aureus* isolates from nasal carriage of health personnel and hospital objects (table1) are comparable with other studies done in Gondar, Pakistan and Cameron (17, 20, 21). The occurrence of *S. aureus* in hospital objects (table2) may indicate poor infection control in the hospital environment, which could serve as a reservoir of the organism and it may be the potential source of cross contamination (infection) between objects and

patients. This may also account for the high incidence of the organism observed in health personnel. Out of 50 isolates of *S. aureus* from health personnel and objects, 19 had identical antibiogram pattern with the isolates of patients. This specifies that the objects and/or the health personnel may be the source of *S. aureus* infection in this study.

Antimicrobial resistance patterns of *S. aureus* infection in the present study (table4) is comparable with the previous study done in Dessie (22), but the susceptibility of ciprofloxacin and ceftriaxone are fall from the previous study which had such antimicrobial susceptibility patterns as 95.4% and 80% respectively. It may be due to overuse of it as empirical treatment.

S. aureus isolated in this study showed the highest vancomycin sensitivity pattern (table4) which is similar with the previous studies in Kontagora and Suleja Area of Niger State, in Gondar and Nigeria (17, 23, 24) The highest susceptibility of *S. aureus* to vancomycin in our study may be due to its uncommon use or being a new medication. In this study; however, *S aureus* was highly resistant to penicillin G, amoxicillin and nalidixic acid (table 4). This result is in line with previous studies in Gondar, Cameron, Dessie and Jimma (24, 25, 28, 25), respectively, but in the case of amoxicillin, our result is completely showed disparity to the study in Bahar-dar (26), which reported *S. aureus* as 100% susceptible. This difference may be due to inappropriate and incorrect administration of antibacterials as empiric therapies and lack of appropriate infection control strategies, which can cause a shift to increase prevalence of resistant organism in the community in the study area. Forty four percent of *S. aureus* isolates were resistant to oxacillin which is similar to the previous studies in Kontagora and Suleja Area of Niger State and Jimma (23, 25).

Multi drug resistance patterns (table 6) of isolates of *S. aureus* in the current study is higher than the previous studies in Gondar (17) and Dessie (22) but in line with the previous study in Gondar (27). This is probably due to empirical use of broad-spectrum antibacterials, lack of culture and antimicrobial susceptibility tests and non adherence to hospital antimicrobial policy. About 24%, 16%, 6%, and 3% of *S. aureus* isolates were found to be resistant to three, four, two and one of the tested antibacterials respectively. No one of the isolates was susceptible to all of the tested antibacterials and also none of the *S. aureus* isolates were pan- resistant (resistant to all the tested antibacterials).

VIII. LIMITATION OF THE STUDY

In the present study, the antimicrobial susceptibility pattern was used in an attempt to identify possible cross infection from health personnel and/or hospital objects has a limitation. Since unrelated colony

of a single species can undergo evolutionary convergence to the same resistance phenotype under antibacterial selective pressure through mutation and genetic exchange (28), unless confirmed by genomic analysis, no definite conclusions can be drawn with regard to the role of the possible sources of infection.

IX. CONCLUSION

The present study indicated that *S. aureus* is still the most common cause of nosocomial infection and hospital objects which were being used by inpatients may be a source of nosocomial *S. aureus* infections in this hospital. It also demonstrated that health personnel are at risk of the infection and can be a potential source of nosocomial *S. aureus* infections. In this study MDR was very high and most of the isolates showed high levels of resistance to commonly used antibacterials. However, gentamicin (84%) had high activity against most of the isolates *in vitro* when compare to other tested antibacterials. Susceptibility rate of *S. aureus* to vacomycin in this study was 100%. In the absence of culture and antibacterial susceptibility testing, vancomycin and gentamicin are the best therapeutic options to treat *S. aureus* infections. In order to confirm *S. aureus* cross infections among patients, health personnel and objects, further study with the aid of phage typing and other molecular studies should be done.

X. ACKNOWLEDGMENT

We would like to thank University of Gondar which covered the financial aspect of this work. Our deepest thank also go to Dessie Regional Health Research Laboratory for supporting the necessary material and equipments required for this research work and to the study participants.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Onwubiko NE, Sadiq NM. Antibiotic sensitivity pattern of Staphylococcus aureus from clinical isolates in a tertiary health institution in Kano, Northwestern Nigeria. *Pan African Medical J.* 2011; 8:4
2. Deleo FR, Otto M, Kreiswirth BN, Chambers H.F. Community-associated meticillinresistant *Staphylococcus aureus*. *Lancet Infect Dis.* 2010; 375 (9725):1557-1568.
3. Chambers HF, Deleo FR. Waves of resistance: *Staphylococcus aureus* in the antibiotic era. *Nat Rev Microbiol.* 2009; 7(9): 629-641.
4. Noskova T. Hygienic-epidemiologic aspects of nosocomial infections. *In: Madar R and Sctefkoviccova M (editors). Nosocomial infections. Selected chapters. Banska Bystrica, Dumas.* 2004; 129-134.

5. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired methicillin resistant *Staphylococcus aureus*: an emerging threat. *Lancet Infect Dis*. 2005; 5: 275–86.
6. Hartmann B, Benson M, Junger A. Computer keyboard and mouse as a reservoir of pathogens in an intensive care unit. *J Clin Monit Comput*. 2004; 18: 7-12.
7. Carling PC, Von Behren SM, Kim P, Woods C, Group HEHS. Intensive care unit environmental cleaning: an evaluation in sixteen hospitals using a novel assessment tool. *J Hosp Infect*. 2008; 68: 39-44.
8. Kluytmans J, Belkum AV, Verbrugh H. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clin. Microbiol. Rev*. 1997; 10(3): 505.
9. Neely AN, Webber JM, Daviau P. Computer equipment used in patient care within a multihospital system: recommendations for cleaning and disinfection. *Am J Infect Control Epidemiol*. 2005; 24: 233-237.
10. Amin AN, Rehm SJ. Infections in hospitalized patients: what is happening and who can help? *Cleve Clin J Med*. 2007; 74 (4): 2-5.
11. Jevons MP: Celbenin-resistant staphylococci. *Br Med J* 1961; 1:124-126.
12. Walsh TR, Howe RA: The prevalence and mechanisms of vancomycin resistance in *Staphylococcus aureus*. *Annu Rev Microbiol*. 2002; 56:657-675.
13. Geyid A, Lemeneh Y. The Incidence of MRSA strain in clinical specimen in relation to their β -lactamase producing & multiple drug resistance properties in Addis Ababa. *Ethiop med. J*. 1991; 29 (4):149-161.
14. United Nations Population Fund (UNFPA). Summary and Statistical Report of the 2007 Population and Housing Census Results. United Nations Population Fund. 2008.
15. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for antimicrobial susceptibility testing. 8th Informational Supplement. M100S12. National Committee for Clinical Laboratory Standards, Villanova. Pa; 2002.
16. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial susceptibility testing Standards M2-A9 and M7-A7. 2007; 27:1.
17. Gelaw A, Gebre SS, Tiruneh M, Fentie M. Antimicrobial susceptibility patterns of bacterial isolates from patients with postoperative surgical site infection, health professionals and environmental samples at a tertiary level hospital northwest Ethiopia. *Int J. Pharm Ind Res*. 2013; 03:06-14.
18. Chikere CB, Omoni VT, Chikere BO. Distribution of potential nosocomial pathogens in a hospital environment. *Afr. J. Biotechnol*. 2008; 7 (20): 3535-3539.
19. Cespedes C, Miller M, Quagliarello B, Vavagiakis P, Klein RS, Lowy FD. Differences between *Staphylococcus aureus* Isolates from Medical and Nonmedical Hospital Personnel. *J. Clin. Microbiol*. 2002; 40: 2594-2597.
20. Farzana K, Rashid Z, Akhtar N, Sattar A, Khan JA, Nasir B. Nasal Carriage of Staphylococci in Health care Workers: Antimicrobial Susceptibility Profile. *Pak. J. Pharm. Sci*. 2008; 21: 290-294.
21. Gonsu KH, Kouemo SL, Toukam M, Ndze VN, Koulla SS. Nasal carriage of methicillin resistant *Staphylococcus aureus* and its antibiotic susceptibility pattern in adult hospitalized patients and medical staff in some hospitals in Cameroon. *J. Microbiol. Antimicrob*. 2013; 5(3): 29-33.
22. Bayeh A, Mulugeta K. Bacteriology and Antimicrobial Susceptibility of Otitis Media at Dessie Regional Health Research Laboratory, Ethiopia. *Ethiop. J. Health Dev*. 2011; 25 (2):161-167.
23. Sanı RA, Garba SA, Oyewole OA, Ibrahim A. Antibiotic Resistance Profile of Gram Positive Bacteria Isolated from Wound Infections in Minna, Bida, Kontagora and Suleja Area of Niger State. *J. Health Sciences*. 2012; 2(3): 19-22.
24. Shittu AO, Okon K, Adesida S, Oyedara O, Witte W, Strommenger B, et al. Antibiotic resistance and molecular epidemiology of *Staphylococcus aureus* in Nigeria. *BMC Microbiology*. 2011; 11:92.
25. Befikadu L, Hailemeskel M, Fetene D. Prevalence and antibiotic susceptibility pattern of staphylococcus aureus strains from inpatients and outpatients in jimma University specialized hospital, jimma, southwest Ethiopia. *Ethiop pharmaceutical J*. 2010; 17:14.
26. Demilie T, Beyene G, Melaku S, Tsegaye W. Urinary bacterial profile and antibiotic susceptibility pattern among pregnant women in northwest Ethiopia. *Ethiop. J Health Sci*. 2012; 22: 2.
27. Alemu A, Moges F, Shiferaw Y, Tafess K, Kassu A, Anagaw B, et al. Bacterial profile and drug susceptibility pattern of urinary tract infection in pregnant women at University of Gondar Teaching Hospital, Northwest Ethiopia. *BMC Research Notes*. 2012; 5: 197.
28. Mori N, Fujino T, Kashima T, Tomioka J, Kawana A, Kawahata H, et al. Epidemiological analysis of nosocomial outbreaks of methicillin resistant *S. aureus* in a surgery ward. *Jpn J Infect Dis*. 2001; 54:159-161.

GLOBAL JOURNALS INC. (US) GUIDELINES HANDBOOK 2014

WWW.GLOBALJOURNALS.ORG

FELLOWS

FELLOW OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (FARSM)

Global Journals Incorporate (USA) is accredited by Open Association of Research Society (OARS), U.S.A and in turn, awards “FARSM” title to individuals. The 'FARSM' title is accorded to a selected professional after the approval of the Editor-in-Chief/Editorial Board Members/Dean.



- The “FARSM” is a dignified title which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., FARSS or William Walldroff, M.S., FARSM.

FARSM accrediting is an honor. It authenticates your research activities. After recognition as FARSM, you can add 'FARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and reputation to your name. You may use it on your professional Counseling Materials such as CV, Resume, and Visiting Card etc.

The following benefits can be availed by you only for next three years from the date of certification:



FARSM designated members are entitled to avail a 40% discount while publishing their research papers (of a single author) with Global Journals Incorporation (USA), if the same is accepted by Editorial Board/Peer Reviewers. If you are a main author or co-author in case of multiple authors, you will be entitled to avail discount of 10%.

Once FARSM title is accorded, the Fellow is authorized to organize a symposium/seminar/conference on behalf of Global Journal Incorporation (USA). The Fellow can also participate in conference/seminar/symposium organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent.



You may join as member of the Editorial Board of Global Journals Incorporation (USA) after successful completion of three years as Fellow and as Peer Reviewer. In addition, it is also desirable that you should organize seminar/symposium/conference at least once.


We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.





The FARSM can go through standards of OARS. You can also play vital role if you have any suggestions so that proper amendment can take place to improve the same for the benefit of entire research community.

As FARSM, you will be given a renowned, secure and free professional email address with 100 GB of space e.g. johnhall@globaljournals.org. This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.



The FARSM will be eligible for a free application of standardization of their researches. Standardization of research will be subject to acceptability within stipulated norms as the next step after publishing in a journal. We shall depute a team of specialized research professionals who will render their services for elevating your researches to next higher level, which is worldwide open standardization.

The FARSM member can apply for grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A. Once you are designated as FARSM, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria. After certification of all your credentials by OARS, they will be published on your Fellow Profile link on website <https://associationofresearch.org> which will be helpful to upgrade the dignity.



The FARSM members can avail the benefits of free research podcasting in Global Research Radio with their research documents. After publishing the work, (including published elsewhere worldwide with proper authorization) you can upload your research paper with your recorded voice or you can utilize chargeable services of our professional RJs to record your paper in their voice on request.



The FARSM member also entitled to get the benefits of free research podcasting of their research documents through video clips. We can also streamline your conference videos and display your slides/ online slides and online research video clips at reasonable charges, on request.





The FARSM is eligible to earn from sales proceeds of his/her researches/reference/review Books or literature, while publishing with Global Journals. The FARSS can decide whether he/she would like to publish his/her research in a closed manner. In this case, whenever readers purchase that individual research paper for reading, maximum 60% of its profit earned as royalty by Global Journals, will be credited to his/her bank account. The entire entitled amount will be credited to his/her bank account exceeding limit of minimum fixed balance. There is no minimum time limit for collection. The FARSM member can decide its price and we can help in making the right decision.

The FARSM member is eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get remuneration of 15% of author fees, taken from the author of a respective paper. After reviewing 5 or more papers you can request to transfer the amount to your bank account.



MEMBER OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (MARSM)

The ' MARSM ' title is accorded to a selected professional after the approval of the Editor-in-Chief / Editorial Board Members/Dean.

The “MARSM” is a dignified ornament which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., MARSM or William Walldroff, M.S., MARSM.




MARSM accrediting is an honor. It authenticates your research activities. After becoming MARSM, you can add 'MARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and repute to your name. You may use it on your professional Counseling Materials such as CV, Resume, Visiting Card and Name Plate etc.

The following benefits can be availed by you only for next three years from the date of certification.



MARSM designated members are entitled to avail a 25% discount while publishing their research papers (of a single author) in Global Journals Inc., if the same is accepted by our Editorial Board and Peer Reviewers. If you are a main author or co-author of a group of authors, you will get discount of 10%.

As MARSM, you will be given a renowned, secure and free professional email address with 30 GB of space e.g. johnhall@globaljournals.org. This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.





We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.



The MARSM member can apply for approval, grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A.



Once you are designated as MARSM, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria.

It is mandatory to read all terms and conditions carefully.



AUXILIARY MEMBERSHIPS

Institutional Fellow of Open Association of Research Society (USA) - OARS (USA)

Global Journals Incorporation (USA) is accredited by Open Association of Research Society, U.S.A (OARS) and in turn, affiliates research institutions as “Institutional Fellow of Open Association of Research Society” (IFOARS).



The “FARSC” is a dignified title which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., FARSC or William Walldroff, M.S., FARSC.

The IFOARS institution is entitled to form a Board comprised of one Chairperson and three to five board members preferably from different streams. The Board will be recognized as “Institutional Board of Open Association of Research Society”-(IBOARS).

The Institute will be entitled to following benefits:



The IBOARS can initially review research papers of their institute and recommend them to publish with respective journal of Global Journals. It can also review the papers of other institutions after obtaining our consent. The second review will be done by peer reviewer of Global Journals Incorporation (USA) The Board is at liberty to appoint a peer reviewer with the approval of chairperson after consulting us.

The author fees of such paper may be waived off up to 40%.

The Global Journals Incorporation (USA) at its discretion can also refer double blind peer reviewed paper at their end to the board for the verification and to get recommendation for final stage of acceptance of publication.




The IBOARS can organize symposium/seminar/conference in their country on behalf of Global Journals Incorporation (USA)-OARS (USA). The terms and conditions can be discussed separately.

The Board can also play vital role by exploring and giving valuable suggestions regarding the Standards of “Open Association of Research Society, U.S.A (OARS)” so that proper amendment can take place for the benefit of entire research community. We shall provide details of particular standard only on receipt of request from the Board.



The board members can also join us as Individual Fellow with 40% discount on total fees applicable to Individual Fellow. They will be entitled to avail all the benefits as declared. Please visit Individual Fellow-sub menu of GlobalJournals.org to have more relevant details.



We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.



After nomination of your institution as “Institutional Fellow” and constantly functioning successfully for one year, we can consider giving recognition to your institute to function as Regional/Zonal office on our behalf. The board can also take up the additional allied activities for betterment after our consultation.

The following entitlements are applicable to individual Fellows:

Open Association of Research Society, U.S.A (OARS) By-laws states that an individual Fellow may use the designations as applicable, or the corresponding initials. The Credentials of individual Fellow and Associate designations signify that the individual has gained knowledge of the fundamental concepts. One is magnanimous and proficient in an expertise course covering the professional code of conduct, and follows recognized standards of practice.



Open Association of Research Society (US)/ Global Journals Incorporation (USA), as described in Corporate Statements, are educational, research publishing and professional membership organizations. Achieving our individual Fellow or Associate status is based mainly on meeting stated educational research requirements.

Disbursement of 40% Royalty earned through Global Journals : Researcher = 50%, Peer Reviewer = 37.50%, Institution = 12.50% E.g. Out of 40%, the 20% benefit should be passed on to researcher, 15 % benefit towards remuneration should be given to a reviewer and remaining 5% is to be retained by the institution.



We shall provide print version of 12 issues of any three journals [as per your requirement] out of our 38 journals worth \$ 2376 USD.

Other:

The individual Fellow and Associate designations accredited by Open Association of Research Society (US) credentials signify guarantees following achievements:

- The professional accredited with Fellow honor, is entitled to various benefits viz. name, fame, honor, regular flow of income, secured bright future, social status etc.



- In addition to above, if one is single author, then entitled to 40% discount on publishing research paper and can get 10% discount if one is co-author or main author among group of authors.
- The Fellow can organize symposium/seminar/conference on behalf of Global Journals Incorporation (USA) and he/she can also attend the same organized by other institutes on behalf of Global Journals.
- The Fellow can become member of Editorial Board Member after completing 3yrs.
- The Fellow can earn 60% of sales proceeds from the sale of reference/review books/literature/publishing of research paper.
- Fellow can also join as paid peer reviewer and earn 15% remuneration of author charges and can also get an opportunity to join as member of the Editorial Board of Global Journals Incorporation (USA)
- • This individual has learned the basic methods of applying those concepts and techniques to common challenging situations. This individual has further demonstrated an in-depth understanding of the application of suitable techniques to a particular area of research practice.

Note :

//

- In future, if the board feels the necessity to change any board member, the same can be done with the consent of the chairperson along with anyone board member without our approval.
- In case, the chairperson needs to be replaced then consent of 2/3rd board members are required and they are also required to jointly pass the resolution copy of which should be sent to us. In such case, it will be compulsory to obtain our approval before replacement.
- In case of “Difference of Opinion [if any]” among the Board members, our decision will be final and binding to everyone.

//



PROCESS OF SUBMISSION OF RESEARCH PAPER

The Area or field of specialization may or may not be of any category as mentioned in 'Scope of Journal' menu of the GlobalJournals.org website. There are 37 Research Journal categorized with Six parental Journals GJCST, GJMR, GJRE, GJMBR, GJSFR, GJHSS. For Authors should prefer the mentioned categories. There are three widely used systems UDC, DDC and LCC. The details are available as 'Knowledge Abstract' at Home page. The major advantage of this coding is that, the research work will be exposed to and shared with all over the world as we are being abstracted and indexed worldwide.

The paper should be in proper format. The format can be downloaded from first page of 'Author Guideline' Menu. The Author is expected to follow the general rules as mentioned in this menu. The paper should be written in MS-Word Format (*.DOC,*.DOCX).

The Author can submit the paper either online or offline. The authors should prefer online submission.Online Submission: There are three ways to submit your paper:

(A) (I) First, register yourself using top right corner of Home page then Login. If you are already registered, then login using your username and password.

(II) Choose corresponding Journal.

(III) Click 'Submit Manuscript'. Fill required information and Upload the paper.

(B) If you are using Internet Explorer, then Direct Submission through Homepage is also available.

(C) If these two are not convenient, and then email the paper directly to dean@globaljournals.org.

Offline Submission: Author can send the typed form of paper by Post. However, online submission should be preferred.



PREFERRED AUTHOR GUIDELINES

MANUSCRIPT STYLE INSTRUCTION (Must be strictly followed)

Page Size: 8.27" X 11"

- Left Margin: 0.65
- Right Margin: 0.65
- Top Margin: 0.75
- Bottom Margin: 0.75
- Font type of all text should be Swis 721 Lt BT.
- Paper Title should be of Font Size 24 with one Column section.
- Author Name in Font Size of 11 with one column as of Title.
- Abstract Font size of 9 Bold, "Abstract" word in Italic Bold.
- Main Text: Font size 10 with justified two columns section
- Two Column with Equal Column with of 3.38 and Gaping of .2
- First Character must be three lines Drop capped.
- Paragraph before Spacing of 1 pt and After of 0 pt.
- Line Spacing of 1 pt
- Large Images must be in One Column
- Numbering of First Main Headings (Heading 1) must be in Roman Letters, Capital Letter, and Font Size of 10.
- Numbering of Second Main Headings (Heading 2) must be in Alphabets, Italic, and Font Size of 10.

You can use your own standard format also.

Author Guidelines:

1. General,
2. Ethical Guidelines,
3. Submission of Manuscripts,
4. Manuscript's Category,
5. Structure and Format of Manuscript,
6. After Acceptance.

1. GENERAL

Before submitting your research paper, one is advised to go through the details as mentioned in following heads. It will be beneficial, while peer reviewer justify your paper for publication.

Scope

The Global Journals Inc. (US) welcome the submission of original paper, review paper, survey article relevant to the all the streams of Philosophy and knowledge. The Global Journals Inc. (US) is parental platform for Global Journal of Computer Science and Technology, Researches in Engineering, Medical Research, Science Frontier Research, Human Social Science, Management, and Business organization. The choice of specific field can be done otherwise as following in Abstracting and Indexing Page on this Website. As the all Global

Journals Inc. (US) are being abstracted and indexed (in process) by most of the reputed organizations. Topics of only narrow interest will not be accepted unless they have wider potential or consequences.

2. ETHICAL GUIDELINES

Authors should follow the ethical guidelines as mentioned below for publication of research paper and research activities.

Papers are accepted on strict understanding that the material in whole or in part has not been, nor is being, considered for publication elsewhere. If the paper once accepted by Global Journals Inc. (US) and Editorial Board, will become the copyright of the Global Journals Inc. (US).

Authorship: The authors and coauthors should have active contribution to conception design, analysis and interpretation of findings. They should critically review the contents and drafting of the paper. All should approve the final version of the paper before submission

The Global Journals Inc. (US) follows the definition of authorship set up by the Global Academy of Research and Development. According to the Global Academy of R&D authorship, criteria must be based on:

- 1) Substantial contributions to conception and acquisition of data, analysis and interpretation of the findings.
- 2) Drafting the paper and revising it critically regarding important academic content.
- 3) Final approval of the version of the paper to be published.

All authors should have been credited according to their appropriate contribution in research activity and preparing paper. Contributors who do not match the criteria as authors may be mentioned under Acknowledgement.

Acknowledgements: Contributors to the research other than authors credited should be mentioned under acknowledgement. The specifications of the source of funding for the research if appropriate can be included. Suppliers of resources may be mentioned along with address.

Appeal of Decision: The Editorial Board's decision on publication of the paper is final and cannot be appealed elsewhere.

Permissions: It is the author's responsibility to have prior permission if all or parts of earlier published illustrations are used in this paper.

Please mention proper reference and appropriate acknowledgements wherever expected.

If all or parts of previously published illustrations are used, permission must be taken from the copyright holder concerned. It is the author's responsibility to take these in writing.

Approval for reproduction/modification of any information (including figures and tables) published elsewhere must be obtained by the authors/copyright holders before submission of the manuscript. Contributors (Authors) are responsible for any copyright fee involved.

3. SUBMISSION OF MANUSCRIPTS

Manuscripts should be uploaded via this online submission page. The online submission is most efficient method for submission of papers, as it enables rapid distribution of manuscripts and consequently speeds up the review procedure. It also enables authors to know the status of their own manuscripts by emailing us. Complete instructions for submitting a paper is available below.

Manuscript submission is a systematic procedure and little preparation is required beyond having all parts of your manuscript in a given format and a computer with an Internet connection and a Web browser. Full help and instructions are provided on-screen. As an author, you will be prompted for login and manuscript details as Field of Paper and then to upload your manuscript file(s) according to the instructions.



To avoid postal delays, all transaction is preferred by e-mail. A finished manuscript submission is confirmed by e-mail immediately and your paper enters the editorial process with no postal delays. When a conclusion is made about the publication of your paper by our Editorial Board, revisions can be submitted online with the same procedure, with an occasion to view and respond to all comments.

Complete support for both authors and co-author is provided.

4. MANUSCRIPT'S CATEGORY

Based on potential and nature, the manuscript can be categorized under the following heads:

Original research paper: Such papers are reports of high-level significant original research work.

Review papers: These are concise, significant but helpful and decisive topics for young researchers.

Research articles: These are handled with small investigation and applications

Research letters: The letters are small and concise comments on previously published matters.

5. STRUCTURE AND FORMAT OF MANUSCRIPT

The recommended size of original research paper is less than seven thousand words, review papers fewer than seven thousands words also. Preparation of research paper or how to write research paper, are major hurdle, while writing manuscript. The research articles and research letters should be fewer than three thousand words, the structure original research paper; sometime review paper should be as follows:

Papers: These are reports of significant research (typically less than 7000 words equivalent, including tables, figures, references), and comprise:

(a) Title should be relevant and commensurate with the theme of the paper.

(b) A brief Summary, "Abstract" (less than 150 words) containing the major results and conclusions.

(c) Up to ten keywords, that precisely identifies the paper's subject, purpose, and focus.

(d) An Introduction, giving necessary background excluding subheadings; objectives must be clearly declared.

(e) Resources and techniques with sufficient complete experimental details (wherever possible by reference) to permit repetition; sources of information must be given and numerical methods must be specified by reference, unless non-standard.


(f) Results should be presented concisely, by well-designed tables and/or figures; the same data may not be used in both; suitable statistical data should be given. All data must be obtained with attention to numerical detail in the planning stage. As reproduced design has been recognized to be important to experiments for a considerable time, the Editor has decided that any paper that appears not to have adequate numerical treatments of the data will be returned un-refereed;

(g) Discussion should cover the implications and consequences, not just recapitulating the results; conclusions should be summarizing.

(h) Brief Acknowledgements.

(i) References in the proper form.

Authors should very cautiously consider the preparation of papers to ensure that they communicate efficiently. Papers are much more likely to be accepted, if they are cautiously designed and laid out, contain few or no errors, are summarizing, and be conventional to the approach and instructions. They will in addition, be published with much less delays than those that require much technical and editorial correction.



The Editorial Board reserves the right to make literary corrections and to make suggestions to improve brevity.

It is vital, that authors take care in submitting a manuscript that is written in simple language and adheres to published guidelines.

Format

Language: The language of publication is UK English. Authors, for whom English is a second language, must have their manuscript efficiently edited by an English-speaking person before submission to make sure that, the English is of high excellence. It is preferable, that manuscripts should be professionally edited.

Standard Usage, Abbreviations, and Units: Spelling and hyphenation should be conventional to The Concise Oxford English Dictionary. Statistics and measurements should at all times be given in figures, e.g. 16 min, except for when the number begins a sentence. When the number does not refer to a unit of measurement it should be spelt in full unless, it is 160 or greater.

Abbreviations supposed to be used carefully. The abbreviated name or expression is supposed to be cited in full at first usage, followed by the conventional abbreviation in parentheses.

Metric SI units are supposed to generally be used excluding where they conflict with current practice or are confusing. For illustration, 1.4 l rather than $1.4 \times 10^{-3} \text{ m}^3$, or 4 mm somewhat than $4 \times 10^{-3} \text{ m}$. Chemical formula and solutions must identify the form used, e.g. anhydrous or hydrated, and the concentration must be in clearly defined units. Common species names should be followed by underlines at the first mention. For following use the generic name should be constricted to a single letter, if it is clear.

Structure

All manuscripts submitted to Global Journals Inc. (US), ought to include:

Title: The title page must carry an instructive title that reflects the content, a running title (less than 45 characters together with spaces), names of the authors and co-authors, and the place(s) wherever the work was carried out. The full postal address in addition with the e-mail address of related author must be given. Up to eleven keywords or very brief phrases have to be given to help data retrieval, mining and indexing.

Abstract, used in Original Papers and Reviews:

Optimizing Abstract for Search Engines

Many researchers searching for information online will use search engines such as Google, Yahoo or similar. By optimizing your paper for search engines, you will amplify the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in a further work. Global Journals Inc. (US) have compiled these guidelines to facilitate you to maximize the web-friendliness of the most public part of your paper.

Key Words

A major linchpin in research work for the writing research paper is the keyword search, which one will employ to find both library and Internet resources.

One must be persistent and creative in using keywords. An effective keyword search requires a strategy and planning a list of possible keywords and phrases to try.

Search engines for most searches, use Boolean searching, which is somewhat different from Internet searches. The Boolean search uses "operators," words (and, or, not, and near) that enable you to expand or narrow your affords. Tips for research paper while preparing research paper are very helpful guideline of research paper.

Choice of key words is first tool of tips to write research paper. Research paper writing is an art. A few tips for deciding as strategically as possible about keyword search:



- One should start brainstorming lists of possible keywords before even begin searching. Think about the most important concepts related to research work. Ask, "What words would a source have to include to be truly valuable in research paper?" Then consider synonyms for the important words.
- It may take the discovery of only one relevant paper to let steer in the right keyword direction because in most databases, the keywords under which a research paper is abstracted are listed with the paper.
- One should avoid outdated words.

Keywords are the key that opens a door to research work sources. Keyword searching is an art in which researcher's skills are bound to improve with experience and time.

Numerical Methods: Numerical methods used should be clear and, where appropriate, supported by references.

Acknowledgements: Please make these as concise as possible.

References

References follow the Harvard scheme of referencing. References in the text should cite the authors' names followed by the time of their publication, unless there are three or more authors when simply the first author's name is quoted followed by et al. unpublished work has to only be cited where necessary, and only in the text. Copies of references in press in other journals have to be supplied with submitted typescripts. It is necessary that all citations and references be carefully checked before submission, as mistakes or omissions will cause delays.

References to information on the World Wide Web can be given, but only if the information is available without charge to readers on an official site. Wikipedia and Similar websites are not allowed where anyone can change the information. Authors will be asked to make available electronic copies of the cited information for inclusion on the Global Journals Inc. (US) homepage at the judgment of the Editorial Board.

The Editorial Board and Global Journals Inc. (US) recommend that, citation of online-published papers and other material should be done via a DOI (digital object identifier). If an author cites anything, which does not have a DOI, they run the risk of the cited material not being noticeable.

The Editorial Board and Global Journals Inc. (US) recommend the use of a tool such as Reference Manager for reference management and formatting.

Tables, Figures and Figure Legends

Tables: Tables should be few in number, cautiously designed, uncrowned, and include only essential data. Each must have an Arabic number, e.g. Table 4, a self-explanatory caption and be on a separate sheet. Vertical lines should not be used.

Figures: Figures are supposed to be submitted as separate files. Always take in a citation in the text for each figure using Arabic numbers, e.g. Fig. 4. Artwork must be submitted online in electronic form by e-mailing them.

Preparation of Electronic Figures for Publication

Even though low quality images are sufficient for review purposes, print publication requires high quality images to prevent the final product being blurred or fuzzy. Submit (or e-mail) EPS (line art) or TIFF (halftone/photographs) files only. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Do not use pixel-oriented software. Scans (TIFF only) should have a resolution of at least 350 dpi (halftone) or 700 to 1100 dpi (line drawings) in relation to the imitation size. Please give the data for figures in black and white or submit a Color Work Agreement Form. EPS files must be saved with fonts embedded (and with a TIFF preview, if possible).

For scanned images, the scanning resolution (at final image size) ought to be as follows to ensure good reproduction: line art: >650 dpi; halftones (including gel photographs) : >350 dpi; figures containing both halftone and line images: >650 dpi.



Color Charges: It is the rule of the Global Journals Inc. (US) for authors to pay the full cost for the reproduction of their color artwork. Hence, please note that, if there is color artwork in your manuscript when it is accepted for publication, we would require you to complete and return a color work agreement form before your paper can be published.

Figure Legends: Self-explanatory legends of all figures should be incorporated separately under the heading 'Legends to Figures'. In the full-text online edition of the journal, figure legends may possibly be truncated in abbreviated links to the full screen version. Therefore, the first 100 characters of any legend should notify the reader, about the key aspects of the figure.

6. AFTER ACCEPTANCE

Upon approval of a paper for publication, the manuscript will be forwarded to the dean, who is responsible for the publication of the Global Journals Inc. (US).

6.1 Proof Corrections

The corresponding author will receive an e-mail alert containing a link to a website or will be attached. A working e-mail address must therefore be provided for the related author.

Acrobat Reader will be required in order to read this file. This software can be downloaded

(Free of charge) from the following website:

www.adobe.com/products/acrobat/readstep2.html. This will facilitate the file to be opened, read on screen, and printed out in order for any corrections to be added. Further instructions will be sent with the proof.

Proofs must be returned to the dean at dean@globaljournals.org within three days of receipt.

As changes to proofs are costly, we inquire that you only correct typesetting errors. All illustrations are retained by the publisher. Please note that the authors are responsible for all statements made in their work, including changes made by the copy editor.

6.2 Early View of Global Journals Inc. (US) (Publication Prior to Print)

The Global Journals Inc. (US) are enclosed by our publishing's Early View service. Early View articles are complete full-text articles sent in advance of their publication. Early View articles are absolute and final. They have been completely reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after sending them. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the conventional way.

6.3 Author Services

Online production tracking is available for your article through Author Services. Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The authors will receive an e-mail with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript.

6.4 Author Material Archive Policy

Please note that if not specifically requested, publisher will dispose off hardcopy & electronic information submitted, after the two months of publication. If you require the return of any information submitted, please inform the Editorial Board or dean as soon as possible.

6.5 Offprint and Extra Copies

A PDF offprint of the online-published article will be provided free of charge to the related author, and may be distributed according to the Publisher's terms and conditions. Additional paper offprint may be ordered by emailing us at: editor@globaljournals.org .



Before start writing a good quality Computer Science Research Paper, let us first understand what is Computer Science Research Paper? So, Computer Science Research Paper is the paper which is written by professionals or scientists who are associated to Computer Science and Information Technology, or doing research study in these areas. If you are novel to this field then you can consult about this field from your supervisor or guide.

TECHNIQUES FOR WRITING A GOOD QUALITY RESEARCH PAPER:

1. Choosing the topic: In most cases, the topic is searched by the interest of author but it can be also suggested by the guides. You can have several topics and then you can judge that in which topic or subject you are finding yourself most comfortable. This can be done by asking several questions to yourself, like Will I be able to carry our search in this area? Will I find all necessary recourses to accomplish the search? Will I be able to find all information in this field area? If the answer of these types of questions will be "Yes" then you can choose that topic. In most of the cases, you may have to conduct the surveys and have to visit several places because this field is related to Computer Science and Information Technology. Also, you may have to do a lot of work to find all rise and falls regarding the various data of that subject. Sometimes, detailed information plays a vital role, instead of short information.

2. Evaluators are human: First thing to remember that evaluators are also human being. They are not only meant for rejecting a paper. They are here to evaluate your paper. So, present your Best.

3. Think Like Evaluators: If you are in a confusion or getting demotivated that your paper will be accepted by evaluators or not, then think and try to evaluate your paper like an Evaluator. Try to understand that what an evaluator wants in your research paper and automatically you will have your answer.

4. Make blueprints of paper: The outline is the plan or framework that will help you to arrange your thoughts. It will make your paper logical. But remember that all points of your outline must be related to the topic you have chosen.

5. Ask your Guides: If you are having any difficulty in your research, then do not hesitate to share your difficulty to your guide (if you have any). They will surely help you out and resolve your doubts. If you can't clarify what exactly you require for your work then ask the supervisor to help you with the alternative. He might also provide you the list of essential readings.

6. Use of computer is recommended: As you are doing research in the field of Computer Science, then this point is quite obvious.

7. Use right software: Always use good quality software packages. If you are not capable to judge good software then you can lose quality of your paper unknowingly. There are various software programs available to help you, which you can get through Internet.

8. Use the Internet for help: An excellent start for your paper can be by using the Google. It is an excellent search engine, where you can have your doubts resolved. You may also read some answers for the frequent question how to write my research paper or find model research paper. From the internet library you can download books. If you have all required books make important reading selecting and analyzing the specified information. Then put together research paper sketch out.

9. Use and get big pictures: Always use encyclopedias, Wikipedia to get pictures so that you can go into the depth.

10. Bookmarks are useful: When you read any book or magazine, you generally use bookmarks, right! It is a good habit, which helps to not to lose your continuity. You should always use bookmarks while searching on Internet also, which will make your search easier.

11. Revise what you wrote: When you write anything, always read it, summarize it and then finalize it.



12. Make all efforts: Make all efforts to mention what you are going to write in your paper. That means always have a good start. Try to mention everything in introduction, that what is the need of a particular research paper. Polish your work by good skill of writing and always give an evaluator, what he wants.

13. Have backups: When you are going to do any important thing like making research paper, you should always have backup copies of it either in your computer or in paper. This will help you to not to lose any of your important.

14. Produce good diagrams of your own: Always try to include good charts or diagrams in your paper to improve quality. Using several and unnecessary diagrams will degrade the quality of your paper by creating "hotchpotch." So always, try to make and include those diagrams, which are made by your own to improve readability and understandability of your paper.

15. Use of direct quotes: When you do research relevant to literature, history or current affairs then use of quotes become essential but if study is relevant to science then use of quotes is not preferable.

16. Use proper verb tense: Use proper verb tenses in your paper. Use past tense, to present those events that happened. Use present tense to indicate events that are going on. Use future tense to indicate future happening events. Use of improper and wrong tenses will confuse the evaluator. Avoid the sentences that are incomplete.

17. Never use online paper: If you are getting any paper on Internet, then never use it as your research paper because it might be possible that evaluator has already seen it or maybe it is outdated version.

18. Pick a good study spot: To do your research studies always try to pick a spot, which is quiet. Every spot is not for studies. Spot that suits you choose it and proceed further.

19. Know what you know: Always try to know, what you know by making objectives. Else, you will be confused and cannot achieve your target.

20. Use good quality grammar: Always use a good quality grammar and use words that will throw positive impact on evaluator. Use of good quality grammar does not mean to use tough words, that for each word the evaluator has to go through dictionary. Do not start sentence with a conjunction. Do not fragment sentences. Eliminate one-word sentences. Ignore passive voice. Do not ever use a big word when a diminutive one would suffice. Verbs have to be in agreement with their subjects. Prepositions are not expressions to finish sentences with. It is incorrect to ever divide an infinitive. Avoid clichés like the disease. Also, always shun irritating alliteration. Use language that is simple and straight forward. put together a neat summary.

21. Arrangement of information: Each section of the main body should start with an opening sentence and there should be a changeover at the end of the section. Give only valid and powerful arguments to your topic. You may also maintain your arguments with records.

22. Never start in last minute: Always start at right time and give enough time to research work. Leaving everything to the last minute will degrade your paper and spoil your work.

23. Multitasking in research is not good: Doing several things at the same time proves bad habit in case of research activity. Research is an area, where everything has a particular time slot. Divide your research work in parts and do particular part in particular time slot.

24. Never copy others' work: Never copy others' work and give it your name because if evaluator has seen it anywhere you will be in trouble.

25. Take proper rest and food: No matter how many hours you spend for your research activity, if you are not taking care of your health then all your efforts will be in vain. For a quality research, study is must, and this can be done by taking proper rest and food.

26. Go for seminars: Attend seminars if the topic is relevant to your research area. Utilize all your resources.



27. Refresh your mind after intervals: Try to give rest to your mind by listening to soft music or by sleeping in intervals. This will also improve your memory.

28. Make colleagues: Always try to make colleagues. No matter how sharper or intelligent you are, if you make colleagues you can have several ideas, which will be helpful for your research.

29. Think technically: Always think technically. If anything happens, then search its reasons, its benefits, and demerits.

30. Think and then print: When you will go to print your paper, notice that tables are not be split, headings are not detached from their descriptions, and page sequence is maintained.

31. Adding unnecessary information: Do not add unnecessary information, like, I have used MS Excel to draw graph. Do not add irrelevant and inappropriate material. These all will create superfluous. Foreign terminology and phrases are not apropos. One should NEVER take a broad view. Analogy in script is like feathers on a snake. Not at all use a large word when a very small one would be sufficient. Use words properly, regardless of how others use them. Remove quotations. Puns are for kids, not grunt readers. Amplification is a billion times of inferior quality than sarcasm.

32. Never oversimplify everything: To add material in your research paper, never go for oversimplification. This will definitely irritate the evaluator. Be more or less specific. Also too, by no means, ever use rhythmic redundancies. Contractions aren't essential and shouldn't be there used. Comparisons are as terrible as clichés. Give up ampersands and abbreviations, and so on. Remove commas, that are, not necessary. Parenthetical words however should be together with this in commas. Understatement is all the time the complete best way to put onward earth-shaking thoughts. Give a detailed literary review.

33. Report concluded results: Use concluded results. From raw data, filter the results and then conclude your studies based on measurements and observations taken. Significant figures and appropriate number of decimal places should be used. Parenthetical remarks are prohibitive. Proofread carefully at final stage. In the end give outline to your arguments. Spot out perspectives of further study of this subject. Justify your conclusion by at the bottom of them with sufficient justifications and examples.

34. After conclusion: Once you have concluded your research, the next most important step is to present your findings. Presentation is extremely important as it is the definite medium through which your research is going to be in print to the rest of the crowd. Care should be taken to categorize your thoughts well and present them in a logical and neat manner. A good quality research paper format is essential because it serves to highlight your research paper and bring to light all necessary aspects in your research.

INFORMAL GUIDELINES OF RESEARCH PAPER WRITING

Key points to remember:

- Submit all work in its final form.
- Write your paper in the form, which is presented in the guidelines using the template.
- Please note the criterion for grading the final paper by peer-reviewers.

Final Points:

A purpose of organizing a research paper is to let people to interpret your effort selectively. The journal requires the following sections, submitted in the order listed, each section to start on a new page.

The introduction will be compiled from reference matter and will reflect the design processes or outline of basis that direct you to make study. As you will carry out the process of study, the method and process section will be constructed as like that. The result segment will show related statistics in nearly sequential order and will direct the reviewers next to the similar intellectual paths throughout the data that you took to carry out your study. The discussion section will provide understanding of the data and projections as to the implication of the results. The use of good quality references all through the paper will give the effort trustworthiness by representing an alertness of prior workings.



Writing a research paper is not an easy job no matter how trouble-free the actual research or concept. Practice, excellent preparation, and controlled record keeping are the only means to make straightforward the progression.

General style:

Specific editorial column necessities for compliance of a manuscript will always take over from directions in these general guidelines.

To make a paper clear

- Adhere to recommended page limits

Mistakes to evade

- Insertion a title at the foot of a page with the subsequent text on the next page
- Separating a table/chart or figure - impound each figure/table to a single page
- Submitting a manuscript with pages out of sequence

In every sections of your document

- Use standard writing style including articles ("a", "the," etc.)
- Keep on paying attention on the research topic of the paper
- Use paragraphs to split each significant point (excluding for the abstract)
- Align the primary line of each section
- Present your points in sound order
- Use present tense to report well accepted
- Use past tense to describe specific results
- Shun familiar wording, don't address the reviewer directly, and don't use slang, slang language, or superlatives
- Shun use of extra pictures - include only those figures essential to presenting results

Title Page:

Choose a revealing title. It should be short. It should not have non-standard acronyms or abbreviations. It should not exceed two printed lines. It should include the name(s) and address (es) of all authors.



Abstract:

The summary should be two hundred words or less. It should briefly and clearly explain the key findings reported in the manuscript-- must have precise statistics. It should not have abnormal acronyms or abbreviations. It should be logical in itself. Shun citing references at this point.

An abstract is a brief distinct paragraph summary of finished work or work in development. In a minute or less a reviewer can be taught the foundation behind the study, common approach to the problem, relevant results, and significant conclusions or new questions.

Write your summary when your paper is completed because how can you write the summary of anything which is not yet written? Wealth of terminology is very essential in abstract. Yet, use comprehensive sentences and do not let go readability for brevity. You can maintain it succinct by phrasing sentences so that they provide more than lone rationale. The author can at this moment go straight to shortening the outcome. Sum up the study, with the subsequent elements in any summary. Try to maintain the initial two items to no more than one ruling each.

- Reason of the study - theory, overall issue, purpose
- Fundamental goal
- To the point depiction of the research
- Consequences, including definite statistics - if the consequences are quantitative in nature, account quantitative data; results of any numerical analysis should be reported
- Significant conclusions or questions that track from the research(es)

Approach:

- Single section, and succinct
- As an outline of job done, it is always written in past tense
- A conceptual should situate on its own, and not submit to any other part of the paper such as a form or table
- Center on shortening results - bound background information to a verdict or two, if completely necessary
- What you account in an abstract must be regular with what you reported in the manuscript
- Exact spelling, clearness of sentences and phrases, and appropriate reporting of quantities (proper units, important statistics) are just as significant in an abstract as they are anywhere else

Introduction:

The **Introduction** should "introduce" the manuscript. The reviewer should be presented with sufficient background information to be capable to comprehend and calculate the purpose of your study without having to submit to other works. The basis for the study should be offered. Give most important references but shun difficult to make a comprehensive appraisal of the topic. In the introduction, describe the problem visibly. If the problem is not acknowledged in a logical, reasonable way, the reviewer will have no attention in your result. Speak in common terms about techniques used to explain the problem, if needed, but do not present any particulars about the protocols here. Following approach can create a valuable beginning:

- Explain the value (significance) of the study
- Shield the model - why did you employ this particular system or method? What is its compensation? You strength remark on its appropriateness from a abstract point of vision as well as point out sensible reasons for using it.
- Present a justification. Status your particular theory (es) or aim(s), and describe the logic that led you to choose them.
- Very for a short time explain the tentative propose and how it skilled the declared objectives.

Approach:

- Use past tense except for when referring to recognized facts. After all, the manuscript will be submitted after the entire job is done.
- Sort out your thoughts; manufacture one key point with every section. If you make the four points listed above, you will need a least of four paragraphs.



- Present surroundings information only as desirable in order hold up a situation. The reviewer does not desire to read the whole thing you know about a topic.
- Shape the theory/purpose specifically - do not take a broad view.
- As always, give awareness to spelling, simplicity and correctness of sentences and phrases.

Procedures (Methods and Materials):

This part is supposed to be the easiest to carve if you have good skills. A sound written Procedures segment allows a capable scientist to replacement your results. Present precise information about your supplies. The suppliers and clarity of reagents can be helpful bits of information. Present methods in sequential order but linked methodologies can be grouped as a segment. Be concise when relating the protocols. Attempt for the least amount of information that would permit another capable scientist to spare your outcome but be cautious that vital information is integrated. The use of subheadings is suggested and ought to be synchronized with the results section. When a technique is used that has been well described in another object, mention the specific item describing a way but draw the basic principle while stating the situation. The purpose is to text all particular resources and broad procedures, so that another person may use some or all of the methods in one more study or referee the scientific value of your work. It is not to be a step by step report of the whole thing you did, nor is a methods section a set of orders.

Materials:

- Explain materials individually only if the study is so complex that it saves liberty this way.
- Embrace particular materials, and any tools or provisions that are not frequently found in laboratories.
- Do not take in frequently found.
- If use of a definite type of tools.
- Materials may be reported in a part section or else they may be recognized along with your measures.

Methods:

- Report the method (not particulars of each process that engaged the same methodology)
- Describe the method entirely
- To be succinct, present methods under headings dedicated to specific dealings or groups of measures
- Simplify - details how procedures were completed not how they were exclusively performed on a particular day.
- If well known procedures were used, account the procedure by name, possibly with reference, and that's all.

Approach:

- It is embarrassed or not possible to use vigorous voice when documenting methods with no using first person, which would focus the reviewer's interest on the researcher rather than the job. As a result when script up the methods most authors use third person passive voice.
- Use standard style in this and in every other part of the paper - avoid familiar lists, and use full sentences.

What to keep away from

- Resources and methods are not a set of information.
- Skip all descriptive information and surroundings - save it for the argument.
- Leave out information that is immaterial to a third party.

Results:

The principle of a results segment is to present and demonstrate your conclusion. Create this part a entirely objective details of the outcome, and save all understanding for the discussion.

The page length of this segment is set by the sum and types of data to be reported. Carry on to be to the point, by means of statistics and tables, if suitable, to present consequences most efficiently. You must obviously differentiate material that would usually be incorporated in a study editorial from any unprocessed data or additional appendix matter that would not be available. In fact, such matter should not be submitted at all except requested by the instructor.



Content

- Sum up your conclusion in text and demonstrate them, if suitable, with figures and tables.
- In manuscript, explain each of your consequences, point the reader to remarks that are most appropriate.
- Present a background, such as by describing the question that was addressed by creation an exacting study.
- Explain results of control experiments and comprise remarks that are not accessible in a prescribed figure or table, if appropriate.
- Examine your data, then prepare the analyzed (transformed) data in the form of a figure (graph), table, or in manuscript form.

What to stay away from

- Do not discuss or infer your outcome, report surroundings information, or try to explain anything.
- Not at all, take in raw data or intermediate calculations in a research manuscript.
- Do not present the similar data more than once.
- Manuscript should complement any figures or tables, not duplicate the identical information.
- Never confuse figures with tables - there is a difference.

Approach

- As forever, use past tense when you submit to your results, and put the whole thing in a reasonable order.
- Put figures and tables, appropriately numbered, in order at the end of the report
- If you desire, you may place your figures and tables properly within the text of your results part.

Figures and tables

- If you put figures and tables at the end of the details, make certain that they are visibly distinguished from any attach appendix materials, such as raw facts
- Despite of position, each figure must be numbered one after the other and complete with subtitle
- In spite of position, each table must be titled, numbered one after the other and complete with heading
- All figure and table must be adequately complete that it could situate on its own, divide from text


Discussion:

The Discussion is expected the trickiest segment to write and describe. A lot of papers submitted for journal are discarded based on problems with the Discussion. There is no head of state for how long a argument should be. Position your understanding of the outcome visibly to lead the reviewer through your conclusions, and then finish the paper with a summing up of the implication of the study. The purpose here is to offer an understanding of your results and hold up for all of your conclusions, using facts from your research and generally accepted information, if suitable. The implication of result should be visibly described. Infer your data in the conversation in suitable depth. This means that when you clarify an observable fact you must explain mechanisms that may account for the observation. If your results vary from your prospect, make clear why that may have happened. If your results agree, then explain the theory that the proof supported. It is never suitable to just state that the data approved with prospect, and let it drop at that.

- Make a decision if each premise is supported, discarded, or if you cannot make a conclusion with assurance. Do not just dismiss a study or part of a study as "uncertain."
- Research papers are not acknowledged if the work is imperfect. Draw what conclusions you can based upon the results that you have, and take care of the study as a finished work
- You may propose future guidelines, such as how the experiment might be personalized to accomplish a new idea.
- Give details all of your remarks as much as possible, focus on mechanisms.
- Make a decision if the tentative design sufficiently addressed the theory, and whether or not it was correctly restricted.
- Try to present substitute explanations if sensible alternatives be present.
- One research will not counter an overall question, so maintain the large picture in mind, where do you go next? The best studies unlock new avenues of study. What questions remain?
- Recommendations for detailed papers will offer supplementary suggestions.

Approach:

- When you refer to information, differentiate data generated by your own studies from available information
- Submit to work done by specific persons (including you) in past tense.
- Submit to generally acknowledged facts and main beliefs in present tense.



ADMINISTRATION RULES LISTED BEFORE
SUBMITTING YOUR RESEARCH PAPER TO GLOBAL JOURNALS INC. (US)

Please carefully note down following rules and regulation before submitting your Research Paper to Global Journals Inc. (US):

Segment Draft and Final Research Paper: You have to strictly follow the template of research paper. If it is not done your paper may get rejected.

- The **major constraint** is that you must independently make all content, tables, graphs, and facts that are offered in the paper. You must write each part of the paper wholly on your own. The Peer-reviewers need to identify your own perceptives of the concepts in your own terms. NEVER extract straight from any foundation, and never rephrase someone else's analysis.
- Do not give permission to anyone else to "PROOFREAD" your manuscript.
- **Methods to avoid Plagiarism is applied by us on every paper, if found guilty, you will be blacklisted by all of our collaborated research groups, your institution will be informed for this and strict legal actions will be taken immediately.)**
- To guard yourself and others from possible illegal use please do not permit anyone right to use to your paper and files.



CRITERION FOR GRADING A RESEARCH PAPER (COMPILATION)
BY GLOBAL JOURNALS INC. (US)

Please note that following table is only a Grading of "Paper Compilation" and not on "Performed/Stated Research" whose grading solely depends on Individual Assigned Peer Reviewer and Editorial Board Member. These can be available only on request and after decision of Paper. This report will be the property of Global Journals Inc. (US).

Topics	Grades		
	A-B	C-D	E-F
<i>Abstract</i>	Clear and concise with appropriate content, Correct format. 200 words or below	Unclear summary and no specific data, Incorrect form Above 200 words	No specific data with ambiguous information Above 250 words
<i>Introduction</i>	Containing all background details with clear goal and appropriate details, flow specification, no grammar and spelling mistake, well organized sentence and paragraph, reference cited	Unclear and confusing data, appropriate format, grammar and spelling errors with unorganized matter	Out of place depth and content, hazy format
<i>Methods and Procedures</i>	Clear and to the point with well arranged paragraph, precision and accuracy of facts and figures, well organized subheads	Difficult to comprehend with embarrassed text, too much explanation but completed	Incorrect and unorganized structure with hazy meaning
<i>Result</i>	Well organized, Clear and specific, Correct units with precision, correct data, well structuring of paragraph, no grammar and spelling mistake	Complete and embarrassed text, difficult to comprehend	Irregular format with wrong facts and figures
<i>Discussion</i>	Well organized, meaningful specification, sound conclusion, logical and concise explanation, highly structured paragraph reference cited	Wordy, unclear conclusion, spurious	Conclusion is not cited, unorganized, difficult to comprehend
<i>References</i>	Complete and correct format, well organized	Beside the point, Incomplete	Wrong format and structuring



INDEX

A

Adnexal · 19
Aminoglycoside · 8
Amphotericin · 33, 34, 35

B

Bronchodilators · 31

C

Ceftriaxone · 31, 46, 48, 50
Chaicumpar · 11
Chakraborty · 26
Chlamyospore · 25
Chromogranin · 15, 16, 19
Ciprofloxacin · 1, 4, 6, 48, 49
Cloxacillin · 8
Co-Trimoxazole · 10
Cryptococcal · 23, 31, 35
Cytomegalo · 25, 27

D

Dehydrogenase · 2
Deorukhkar · 26, 28
Desferrioxamine · 3

E

Eczematous · 38

F

Flucloxacillin · 8
Fluconazole · 34

H

Haematoxylin · 15

I

Immunohistochemically · 19
Itraconazole · 33, 34, 35

K

Klebsiella · 31

L

Leukemia · 19, 33
Leukocytosis · 31
Lymphopenia · 33

M

Mithicillin · 1, 4, 6

N

Neuroendocrine · 15, 21
Nosocomial · 8, 35, 44, 51
Novobiocin · 2

O

Oropharynx · 33, 35
Osteomyelitis · 42

S

Siripornmongcolchai · 11
Squamous · 15, 19
Staphylococci · 1, 3, 10, 12, 52
Sulfamethoxazole · 10, 39

T

Tachypnea · 31
Trimethoprim · 10, 39
Trophozoites · 23

V

Vancomycin · 8, 10, 42, 44, 46, 48, 50, 52




save our planet



Global Journal of Medical Research

Visit us on the Web at www.GlobalJournals.org | www.JournalofScience.org
or email us at helpdesk@globaljournals.org

ISSN 9755896



© Global Journals